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A B S T R A C T
Background
Oral leukoplakia is a relatively common oral lesion that, in a small proportion of people, precedes the development of oral cancer. Most
leukoplakias are asymptomatic; therefore, the primary objective of treatment should be to prevent onset of cancer. This review updates
our previous review, published in 2006.
Objectives
To assess the effectiveness, safety and acceptability of treatments for leukoplakia in preventing oral cancer.
Search methods
We searched the following electronic databases: Cochrane OralHealth’s Trials Register (to 16May 2016), the Cochrane Central Register
of Controlled Trials (CENTRAL) (the Cochrane Library, 2016, Issue 4), MEDLINE Ovid (1946 to 16 May 2016), Embase Ovid
(1980 to 16 May 2016) and CancerLit via PubMed (1950 to 16 May 2016). We searched the metaRegister of Controlled Trials (to
10 February 2015), ClinicalTrials.gov (to 16 May 2016) and the World Health Organization (WHO) International Clinical Trials
Registry Platform for ongoing trials (to 16 May 2016). We placed no restrictions on the language or date of publication when searching
electronic databases.
Selection criteria
We included randomised controlled trials (RCTs) that enrolled people with a diagnosis of oral leukoplakia and compared any treatment
versus placebo or no treatment.
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Data collection and analysis
We collected data using a data extraction form. Oral cancer development, demonstrated by histopathological examination, was our
primary outcome. Secondary outcomes were clinical resolution of the lesion, improvement of histological features and adverse events.
We contacted trial authors for further details when information was unclear. When valid and relevant data were available, we conducted
a meta-analysis of the data using a fixed-effect model when we identified fewer than four studies with no heterogeneity. For dichoto-
mous outcomes, we calculated risk ratios (RRs) and 95% confidence intervals (CIs). We assessed risk of bias in studies by using the
Cochrane tool. We assessed the overall quality of the evidence by using standardised criteria (Grades of Recommendation, Assessment,
Development and Evaluation Working Group (GRADE)).
Main results
We included 14 studies (909 participants) in this review. Surgical interventions, including laser therapy and cryotherapy, have never
been studied by means of an RCT that included a no treatment or placebo arm. The included trials tested a range of medical and
complementary treatments, in particular, vitamin A and retinoids (four studies); beta carotene or carotenoids (three studies); non-
steroidal anti-inflammatory drugs (NSAIDs), specifically ketorolac and celecoxib (two studies); herbal extracts (four studies), including
tea components, a Chinese herbal mixture and freeze-dried black raspberry gel; bleomycin (one study); and Bowman-Birk inhibitor
(one study).
We judged one study to be at low risk of bias, seven at unclear risk and six at high risk. In general, we judged the overall quality of the
evidence to be low or very low, so findings are uncertain and further research is needed.
Five studies recorded cancer incidence, only three of which provided useable data. None of the studies provided evidence that active
treatment reduced the risk of oral cancer more than placebo: systemic vitamin A (RR 0.11, 95% CI 0.01 to 2.05; 85 participants, one
study); systemic beta carotene (RR 0.71, 95% CI 0.24 to 2.09; 132 participants, two studies); and topical bleomycin (RR 3.00, 95%
CI 0.32 to 27.83; 20 participants, one study). Follow-up ranged between two and seven years.
Some individual studies suggested effectiveness of some proposed treatments, namely, systemic vitamin A, beta carotene and lycopene,
for achieving clinical resolution of lesions more often than placebo. Similarly, single studies found that systemic retinoic acid and
lycopene may provide some benefit in terms of improvement in histological features. Some studies also reported a high rate of relapse.
Side effects of varying severity were often described; however, it seems likely that interventions were well accepted by participants
because drop-out rates were similar between treatment and control groups.
Authors’ conclusions
Surgical treatment for oral leukoplakia has not been assessed in an RCT that included a no treatment or placebo comparison. Nor
has cessation of risk factors such as smoking been assessed. The available evidence on medical and complementary interventions for
treating people with leukoplakia is very limited. We do not currently have evidence of a treatment that is effective for preventing the
development of oral cancer. Treatments such as vitamin A and beta carotene may be effective in healing oral lesions, but relapses and
adverse effects are common. Larger trials of longer duration are required to properly evaluate the effects of leukoplakia treatments on
the risk of developing oral cancer. High-quality research is particularly needed to assess surgical treatment and to assess the effects of
risk factor cessation in people with leukoplakia.
P L A I N L A N G U A G E S U M M A R Y
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Review question
People with oral leukoplakia are at higher risk of developing oral cancer than those with normal oral mucosa. This review, produced
through Cochrane Oral Health, seeks to evaluate whether people affected by leukoplakia can benefit from surgical, medical or com-
plementary treatments, either local or systemic. In particular, we conducted this review to find out which, if any, treatment is able to
prevent people with leukoplakia of the mouth from getting oral cancer. This review updates our previous review published in 2006.
Background
Oral leukoplakia is a white patch formed in the mouth lining that cannot be rubbed off. It often does not hurt and may go unnoticed
for years. People with leukoplakia develop oral cancer more often than people without it. Preventing this is critical because rates of oral
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cancer survival longer than five years after diagnosis are low. Drugs, surgery and other therapies have been tried for treatment of oral
leukoplakia.
Objectives
This review aimed to evaluate whether treatments for oral leukoplakia are effective in preventing oral cancer, and safe and acceptable
to patients.
Study characteristics
The evidence on which this review is based is up-to-date as of May 2016. We found 14 randomised controlled trials (RCTs) of medical
and complementary treatments, which involved 909 participants in total. Treatments included herbal extracts, anti-inflammatory drugs,
vitamin A, beta carotene supplements and others. Surgical treatment has not been compared with placebo or no treatment in an RCT.
Key results
Cancer development was measured in studies of three treatments: systemic vitamin A, systemic beta carotene and topical bleomycin.
None of these treatments showed effectiveness in preventing cancer development, as measured up to two years for vitamin A and beta
carotene, and seven years for bleomycin.
Some individual studies of vitamin A and beta carotene suggested that these treatments may be effective for improving or healing oral
lesions. However, some studies observed a high rate of relapse in participants whose lesions were initially resolved by treatment.
Most treatments caused side effects of differing severity in a high proportion of participants.
It seems likely that interventions were well accepted by participants because drop-out rates were similar between treatment and control
groups.
Quality of the evidence
The available evidence is very limited. Most interventions were assessed by only one small study. Most studies had problems in the way
they were conducted, making their results unreliable. We judged the quality of evidence for the outcome of cancer development to be
very low.
Author conclusions
Larger, better studies of longer duration are required. As well as further studies of drug treatment and alternative treatments like
vitamins, studies are needed to evaluate the effectiveness and safety of surgery, and of stopping risk factor habits such as smoking.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Systemic or topical vitamin A vs placebo for treating leukoplakia
Patient or population: people with oral leukoplakia
Intervention: vitamin A or ret inoids
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with vitamin A or
retinoids
Cancer development at
24 months f rom start
of treatment (treatment
lasted 12 months)
93 per 1000 10 per 1000
(1 to 191)
RR 0.11
(0.01 to 2.05)
85
(1 RCT)
⊕©©©
very lowa
This study evaluated
systemic treatment
Clinical resolut ion (not
completely resolved) at
4 to 12 months
Studies could not be combined in meta-analysis
One study evaluated topical treatment and did not f ind evidence of benef it
3 studies of systemic vitamin A - 2 showed benef it in terms of clinical resolut ion, and 1 did not
Histological changes
(not improved) at 3
months
889 per 1000 382 per 1000 (213 to
676)
RR 0.43 (0.24 to 0.76) 41
(1 RCT)
⊕⊕⊕©
moderateb
This study evaluated
systemic treatment
Safety of the interven-
t ion at 4 to 12 months
3 studies (1 each evaluat ing topical acitret in, topical 13-cis-ret inoic acid, 200,000 IU per week of vitamin A) found no adverse ef fects. Systemic 13-
cis-ret inoic acid (1 to 2 mg/ kg/ d) caused adverse ef fects of varying severity in 79% of part icipants
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI)
CI = conf idence interval; RR = risk rat io; vs = versus; d = day
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
∗From event rate in control group
aDowngraded 3 levels as single small study at unclear risk of bias with very imprecise result
bDowngraded as single small study
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B A C K G R O U N D
Description of the condition
“The term leukoplakia should be used to recognize white plaques
of questionable risk having excluded (other) known diseases or
disorders that carry no increased risk for cancer” (Warnakulasuriya
2007). Such a definition is the result of the efforts of an inter-
national working group comprising specialists in the elds of epi-
demiology, oral medicine, pathology and molecular biology with
a special interest in cancer and precancer, who met in London
in 2005. This meeting was co-ordinated by the World Health
Organization (WHO) Collaborating Centre for Oral Cancer and
Precancer in the UK, to review definitions, classifications, natu-
ral history and management of potentially malignant disorders on
the basis of previously published work (Axell 1984; Axell 1996;
Kramer 1978) and new scientific acquisitions. Thus, ’leukoplakia’
is a clinical term that is used when the clinician has excluded any
other condition of the oral mucosa that can present as a white
lesion (e.g. frictional keratosis, lichen planus, white sponge nevus,
hairy leukoplakia). Such lesions warrant biopsy and histopatho-
logical examination to assess the possible presence of epithelial
dysplasia or carcinoma. Leukoplakia is often associated with to-
bacco smoking or chewing, although idiopathic forms are not rare
(Axell 1987). The role of alcohol, viruses and systemic conditions
needs further investigation (Dietrich 2004; Syrjänen 2011).
Clinical variants of leukoplakia are often classified into two groups:
(1) homogeneous leukoplakia, a lesion of uniform flat appearance
that may exhibit superficial irregularities, but with consistent tex-
ture throughout; and (2) non-homogeneous leukoplakia, a pre-
dominantly white or white and red lesion (erythroleukoplakia)
with an irregular texture that may include ulceration and may
be characterised by a speckled, nodular or verrucous topography.
Histological features of both forms of leukoplakia are variable and
may include ortho-keratosis or para-keratosis of various degrees,
acanthosis or atrophy of the squamous epithelium, mild inflam-
mation in the corium, dysplastic changes of various grades (i.e.
mild, moderate or severe), carcinoma in situ or carcinoma. Some
cases of predominantly white lesions that are difficult to diagnose,
in spite of the availability of a biopsy.
Leukoplakia is not uncommon, and although it is highly variable
among geographical areas and demographic groups, the prevalence
of leukoplakia in the general population varies from less than 1%
to more than 5% (Axell 1984; Axell 1987; Bouquot 1986; Ikeda
1991; Reichart 2000). In a systematic review that included studies
with more than 1000 individuals, the pooled prevalence was esti-
mated to be between 1.49% and 4.27% (Petti 2003). Incidence
data are very scarce. A study from Japan reported an age-adjusted
incidence rate per 100,000 person-years of 409.2 among males
and 70 among females (Nagao 2005), and an Indian study, con-
ducted in a population with distinctive risk factors for oral cancer,
reported lower figures: 240 among males and 3 among females
(Gupta 1980).
Leukoplakia is one of a group of conditions defined as poten-
tially malignant disorders (i.e. “morphological alterations amongst
which some may have an increased potential for malignant trans-
formation, [they] are also indicators of risk of likely future ma-
lignancies elsewhere in (clinically normal appearing) oral mucosa
and not only site specific predictors”) (Warnakulasuriya 2007).
The rate of malignant transformation into squamous cell carci-
noma varies from almost 0% to 36.4% (Arduino 2013), and a
study investigating the natural limit of malignant transformation
on the basis of European epidemiological data concluded that the
upper limit of the annual transformation rate of oral leukoplakia
is unlikely to exceed 1% (Scheifele 2003).
Non-homogeneous leukoplakias carry a higher degree of risk
of transformation when compared with homogeneous variants.
Among patients with a histopathological diagnosis of dysplasia,
about 1/10 of the total may be at higher risk. Other reported risk
factors of statistical significance for cancer development in people
with leukoplakia include female gender, long duration of leuko-
plakia, non-smoking status, location on the lateral tongue and/
or floor of the mouth, size > 200 mm2 (Holmstrup 2006) and
the presence of Candida albicans (Van der Waal 2009). Studies
investigating biomarkers and histological features have suggested
methods that can be used to identify which patients with leuko-
plakia will develop oral cancer, and which will not (Pitiyage 2009;
Smith 2009); however, a definitive, evidence-based and clinically
useful predictor of malignant transformation for dysplastic and
non-dysplastic leukoplakias is not available at the moment. Ane-
uploid lesions (i.e. with abnormal DNA content) are more likely
to transform to cancer compared with diploid lesions (i.e. with
normal DNA content) (Sperandio 2013; Torres-Rendon 2009).
Description of the intervention
Most leukoplakias are asymptomatic; therefore, the need for treat-
ment is based primarily on the precancerous nature of the lesion,
and the primary aim of management should be to avoid develop-
ment of cancer. This is particularly important in view of the poor
prognosis associated with oral squamous cell carcinoma, in which
only about 50% of patients are still alive five years after diagnosis
(Scully 2009), and of the morbidity associated with oral cancer
and complications of oral cancer therapy (Epstein 2012).
Many approaches to the treatment of leukoplakia have been pro-
posed in an attempt to prevent cancer development and to evaluate
clinical/histological resolution of oral leukoplakias (Lodi 2008).
These approaches include surgical excision with different tech-
niques (scalpel, cryosurgery, photodynamic therapy, laser surgery
and vaporisation), medical treatment (topical or systemic), cessa-
tion of risk activities (smoking and alcohol) and no intervention
but strict surveillance.
6Interventions for treating oral leukoplakia to prevent oral cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How the intervention might work
The rationale of surgical excision is that removing the clinically
altered tissue could prevent the onset of oral cancer. For medi-
cal treatments, the rationale depends on the mechanism of ac-
tion of the agent employed: retinoids, vitamin A and carotenoids
might influence epithelial turnover; non-steroidal anti-inflamma-
tory drugs (NSAIDs) block cyclo-oxygenase activity, therebymod-
ulating specific prostaglandins possibly involved in carcinogene-
sis; and chemotherapeutic agents act directly on early neoplastic
cells. As many of these treatments have potentially serious adverse
effects, the “wait and see” approach, based on strict clinical and
histological surveillance, is generally employed to identify early
cancer onset and to initiate cancer treatment to render the best
possible prognosis. Although surgery and medical treatments aim
to remove or reduce the lesion, it must be stressed that no evidence
has shown a relationship between changes in size or resolution and
decreased risk of oral cancer.
Why it is important to do this review
Cochrane Oral Health undertook an extensive prioritisation exer-
cise in 2014 to identify a core portfolio of titles that were the most
clinically important reviews to maintain in The Cochrane Library
(Worthington 2015). This review was identified as a priority ti-
tle by the oral medicine expert panel (Cochrane OHG priority
review portfolio). Treatment of leukoplakia continues to be based
on expert opinion, and more research is needed. This review aims
to provide evidence-based support for clinicians and patients and
a clinical research agenda for planning future studies.
O B J E C T I V E S
To assess the effectiveness, safety and acceptability of treatments
for leukoplakia in preventing oral cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing effects of surgery,
medical or complementary treatments (local or systemic) or risk
factor cessation versus placebo.
Types of participants
Anyone with a diagnosis of oral leukoplakia (without histopatho-
logical evidence of carcinoma) as defined, at the time of the stud-
ies, by consensus conferences held in 1978, 1983, 1994 and 2005
(Axell 1984; Axell 1996; Kramer 1978, Warnakulasuriya 2007).
Types of interventions
Active
• Surgical removal of the lesion, including surgical excision,
laser surgery, cryotherapy
• Systemic medical treatment
• Topical medical treatment, including anti-inflammatory
agents, antimycotic agents, carotenoids and retinoids, cytotoxic
agents, etc.
• Removal of predisposing habits (e.g. tobacco, alcohol)
• Other treatment (e.g. photodynamic therapy)
• Combined treatment
Control
• Placebo
• No treatment
Types of outcome measures
In light of the pre-cancerous nature of leukoplakia, the primary
objective of treatment is to prevent cancer development.
Primary outcomes
• Oral cancer development, demonstrated by
histopathological examination
Secondary outcomes
• Clinical resolution, in terms of the proportion of lesions
that did not resolve (with relapse data when provided)
• Improvement of histological features, in terms of the
proportion of lesions that did not show improvement in
histological features
• Safety of the intervention, as measured by the incidence of
adverse effects
Search methods for identification of studies
To identify studies included in or considered for this review, we de-
veloped detailed search strategies for each database searched. These
were based on the search strategy developed for MEDLINE Ovid
but revised appropriately for each database. The search strategy
used a combination of controlled vocabulary and free text terms
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and was linked with the Cochrane Highly Sensitive Search Strat-
egy (CHSSS) for identifying randomised controlled trials (RCTs)
in MEDLINE: sensitivity-maximising version (2008 revision) as
referenced in Chapter 6.4.11.1 and detailed in Box 6.4.c of the
Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011) (Higgins 2011). We have provided
details of the MEDLINE search in Appendix 1.
Electronic searches
We searched the following databases.
• Cochrane Oral Health’s Trials Register (to 16 May 2016)
(see Appendix 2);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (the Cochrane Library, 2016, Issue 4) (see
Appendix 3);
• MEDLINE Ovid (1946 to 16 May 2016) (see Appendix 1);
• Embase Ovid (1980 to 16 May 2016) (see Appendix 4);
• CancerLit via PubMed (1950 to 16 May 2016) (see
Appendix 5).
We placed no restrictions on the language or date of publication
when searching the electronic databases.
Searching other resources
We searched the following databases for ongoing trials (see
Appendix 6 for details of the search strategy).
• metaRegister of Controlled Trials (to 10 February 2015);
• ClinicalTrials.gov (to 16 May 2016);
• The WHO International Clinical Trials Registry Platform
(to 16 May 2016).
We manually checked the reference lists of included studies and
existing reviews. ThemetaRegister ofControlledTrials is no longer
available and so was not searched in May 2016.
Data collection and analysis
Selection of studies
Two review authors (GL and RF) separately examined the title and
abstract of each article identified by the different search strategies.
When at least one review author considered the article relevant,
it progressed in the review process and was included in a digital
archive prepared by using dedicated software. We obtained full
reports for all relevant studies.
Data extraction and management
All studies meeting the inclusion criteria underwent data extrac-
tion performed by at least two review authors, using a specially
designed form. We present the characteristics of trial partici-
pants, interventions and outcomes for the included trials in the
Characteristics of included studies tables.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of in-
cluded trials and resolved disagreements through discussion and
consensus. We used the recommended approach for assessing risk
of bias in studies included in Cochrane reviews (Higgins 2011a).
This approach addresses the following seven specific domains.
• Random sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants and personnel (performance bias)
• Blinding of outcome assessment (detection bias)
• Incomplete outcome data (attrition bias)
• Selective reporting (reporting bias)
• Other bias
Each domain in the tool includes one or more specific entries in
a ‘Risk of bias’ table. Within each entry, the first part of the tool
describes what was reported to have happened in the study, in
sufficient detail to support a judgement about risk of bias. The
second part of the tool assigns a judgement related to the risk of
bias for that entry - ‘low risk’, ‘high risk’ or ‘unclear risk’. After
taking into account the additional information provided by trial
authors, we summarised the risk of bias in included studies as
follows.
• Low risk of bias: low risk of bias for all key domains
• Unclear risk of bias: unclear risk of bias for one or more key
domains
• High risk of bias: high risk of bias for one or more key
domains
We completed a ’Risk of bias’ table for each included study (see
Characteristics of included studies) and presented results graphi-
cally by study (Figure 1) and by domain over all studies (Figure
2).
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Measures of treatment effect
The primary measure of intervention effect was onset of oral can-
cer. Dichotomous data were reported for this outcome measure:
cancer development versus absence of cancer development.
Secondary outcomes, clinical resolution, histological changes and
adverse effects were usually reported as ordinal measures. We di-
chotomised data: clinical resolution vs partial or no clinical re-
sponse; decreased severity vs worsening of histology or no change
in histological features.
For each intervention, we sought and summarised data on the
number of participants fromboth intervention and control groups
who experienced the event (outcome) and the total number of
participants. We analysed dichotomous data by calculating risk
ratios. As we anticipated pooling data from studies in which true
treatment effects were likely to differ, we planned to use a random-
effects model in statistical analyses; however, we used a fixed-effect
model because of the very small number of studies combined.
Unit of analysis issues
The individual participant was the unit of analysis.
Dealing with missing data
Whenever possible, we obtained missing data from tables and
graphs or through personal contact with study authors. When this
was not possible, and we found no evidence that data weremissing
because of a specific bias, we analysed only available data (Higgins
2011). This represents a change from the previous version of the
review, in which missing data were imputed with the assumption
that all were poor outcomes.
Assessment of heterogeneity
We assessed the significance of discrepancies in the estimates of
treatment effects provided by different trials by using Cochran’s
test for heterogeneity and the I² statistic; the latter describes the
percentage total variation across studies that is due to heterogeneity
rather than to chance. Heterogeneity was considered statistically
significant if the P value was less than 0.1. A rough guide to the
interpretation of I² given in the Cochrane Handbook for Systematic
Reviews of Interventions is as follows: 0 to 40% might not be im-
portant, 30% to 60%may representmoderate heterogeneity, 50%
to 90% may represent substantial heterogeneity, 75% to 100%
represents very substantial (’considerable’) heterogeneity (Higgins
2011).
Assessment of reporting biases
We attempted to minimise reporting biases by conducting a thor-
ough search of multiple sources including trial registries, and by
making efforts to identify unpublished trials and non-English lan-
guage publications.
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Data synthesis
When valid and relevant data were collected, we undertook a
meta-analysis of the data. We grouped and analysed studies on
the basis of intervention category. We conducted meta-analyses
in Review Manager software, using the Mantel-Haenszel method
with a fixed-effect model. We had planned to use a random-effects
model, but this would not have been appropriate because of the
small number of studies included. We did not pool data when
substantial heterogeneity was identified.
Subgroup analysis and investigation of heterogeneity
We had planned to conduct subgroup analyses for smoking and
non-smoking participants, and for lesions with or without dys-
plasia. Unfortunately, as such data were not available, we did not
perform subgroup analyses.
Sensitivity analysis
Wehad planned to undertake sensitivity analysis excluding studies
at high risk and at unclear risk of bias.
Summarising findings and assessing the quality of the
evidence
We constructed ’Summary of findings’ tables for each comparison
to present the results for our review outcomes. We assessed the
quality of the evidence using GRADE (Grades of Recommenda-
tion, Assessment, Development and Evaluation Working Group)
criteria.
R E S U L T S
Description of studies
See Characteristics of included studies, Characteristics of excluded
studies and Characteristics of ongoing studies.
Results of the search
This review was originally published in 2001, and updates were
published in 2004 and 2006. Since its first publication up until
May 2016, we have identified a total of 3438 articles through the
search strategy. We have examined titles and abstracts for eligibil-
ity and have eliminated those not matching the inclusion criteria.
We identified 68 apparently eligible studies and rejected 30 be-
cause they were not pertinent. Nine of the studies are ongoing (see
Characteristics of ongoing studies for details). After we obtained
the full-text version of the remaining 29 studies, we excluded 13
additional studies (Characteristics of excluded studies) - one be-
cause it was quasi-randomised, four because of inadequate alloca-
tion, four for problems in selection of participants and four for lack
of an adequate control group.We categorised two studies as await-
ing classification (Califano 2012; Chiba 2012; Characteristics of
studies awaiting classification). Thus we included 14 studies in
this review. See Figure 3.
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Figure 3. Study flow diagram
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Included studies
Characteristics of trial setting and design
Location
Of the 15 studies included, six were conducted in the USA
(Armstrong 2013; Hong 1986; Mallery 2014; Mulshine
2004; Papadimitrakopoulou 2008; Tsao 2009), three in India
(Sankaranarayan 1997; Singh 2004; Stich 1988), one in Italy
(Piattelli 1999), two in China (Li 1999; Sun 2009), one in Canada
(Epstein 1994) and one in Japan (Nagao 2015). The setting for
all studies was a university hospital.
Design
Ten trials had a two-arm parallel design (Armstrong 2013; Epstein
1994;Hong 1986; Li 1999;Mallery 2014;Mulshine 2004; Nagao
2015; Piattelli 1999; Stich 1988; Sun 2009); three, a three-
arm parallel design (Papadimitrakopoulou 2008; Sankaranarayan
1997; Singh 2004); and one, a four-arm parallel design (Tsao
2009). In three of the four studies with more than two arms, we
pooled together data from the active arms: interventions differed
in dosage in Papadimitrakopoulou 2008; Singh 2004; and Tsao
2009.
Duration
The trials varied in length. Three studies used an open follow-
up (Epstein 1994; Nagao 2015; Tsao 2009); one study lasted two
years (Sankaranarayan 1997); and all other studies lasted less than
one year.
Funding
Two trials did not specify any funding source (Epstein 1994;
Sankaranarayan 1997). In two trials, some study authors worked
for the company that supplied the study drug (Mulshine 2004;
Tsao 2009); in another, the first study author had ownership inter-
est in the patent of the drug tested (Mallery 2014). One study was
supported by Central Soya Company and NIH (National Insti-
tutes of Health) (Armstrong 2013), one by Hoffmann-La Roche
and the National Cancer Institute (Hong 1986), one by the Chi-
nese National Natural Science Foundation (Li 1999), one byNIH
(Mallery 2014), one by the National Cancer Institute Specialized
Programs of Reasearch Excellence (SPORE) Program (Mulshine
2004), one by the Butterfield Award of the Sasakawa Founda-
tion GB and DSM Nutrition Japan (Nagao 2015), one by Pfizer
(Papadimitrakopoulou 2008), one by the Italian National Re-
search Council (CNR) and the Italian Ministry of University, Re-
search, Science andTechnology (MURST) (Piattelli 1999), one by
Jagsonpal Pharmaceuticals Ltd., New Delhi, India (Singh 2004),
one by the National Cancer Institute of Canada (Stich 1988), one
by the Beijing Natural Science Foundation, the National Natural
Science Foundation of China and the Tenth 5-Year Plan of Na-
tional Key Technologies R&D Program in China and NIH (Sun
2009) and one by Ito En Ltd. (Tsao 2009).
Characteristics of participants
The total number of participants randomised in the trials was 909,
with a mean of 64.9 participants per study (ranged from 10 to
131 participants).
The reported proportion of smoking and drinking participants
(the two main risk factors for oral cancer) varied from 8%
(Papadimitrakopoulou 2008) to 86% (Mulshine 2004), and from
9% (Sun 2009) to 71% (Mulshine 2004), respectively. Use of to-
bacco products (Mallery 2014) and smoking (Nagao 2015) were
exclusion criteria in two studies. None of the study authors re-
ported significant changes in these habits during the course of the
trial. In two studies, all participants recruited were chewers of to-
bacco-containing betel quid (another well-known risk factor for
oral cancer) from the same Indian village (Trivandrum, Kerala)
(Sankaranarayan 1997; Stich 1988). All participants enrolled in
the studies underwent a confirmatory biopsy; however, only four
studies reported the histological criteria employed (Epstein 1994;
Papadimitrakopoulou 2008; Stich 1988; Sun 2009). Seven studies
reported the percentage of dysplastic lesions, which ranged from
18.75% (Sun 2009) to 73.2% (Tsao 2009) (see Table 1). One
study excluded lesionswith severe dysplasia (Li 1999), and another
study included cases with at least one of the following features: at
least mild dysplasia, high-risk location, significant extent of tissue
involvement and presence of symptoms (Tsao 2009).
Characteristics of interventions
We did not identify any RCTs that compared surgical treatments
with placebo or no treatment, nor did we identify any RCTs of
risk factor cessation. All included trials compared medical or com-
plementary treatment versus placebo, usually a preparation sim-
ilar to the treatment, without the active ingredient; in one case,
the placebo contained vitamin C, which we considered an inactive
ingredient (Nagao 2015).
Four RCTs compared topical treatment versus placebo (129 par-
ticipants) (Epstein 1994; Mallery 2014; Mulshine 2004; Piattelli
1999), and nine RCTs compared systemic treatment versus
placebo (716 participants) (Armstrong 2013; Hong 1986; Nagao
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2015; Papadimitrakopoulou 2008; Sankaranarayan 1997; Singh
2004; Stich 1988; Sun 2009; Tsao 2009). One RCT compared
a combination of topical and systemic treatments versus placebo
(64 participants) (Li 1999).
Four studies tested vitamin A or retinoids (Hong 1986; Piattelli
1999; Sankaranarayan 1997; Stich 1988); three studies tested
beta carotene or carotenoids (Nagao 2015; Sankaranarayan 1997;
Singh 2004); two studies tested NSAIDs: ketorolac (Mulshine
2004) and celecoxib (Papadimitrakopoulou 2008); and four
studies tested herbal extracts, in particular, tea components (Li
1999 - mixed; Tsao 2009 - green tea extract capsules), a Chi-
nese herbal mixture (Sun 2009) and gel containing freeze-dried
black raspberries (Mallery 2014). The other interventions tested
were bleomycin (Epstein 1994) and Bowman-Birk inhibitor
(Armstrong 2013).
Characteristics of outcomes
Five studies reported data on oral cancer development (Epstein
1994; Nagao 2015; Papadimitrakopoulou 2008; Sankaranarayan
1997; Tsao 2009). In Epstein’s trial, although seven out of 12
participants in the control group received the active treatment at
the end of the study period, we conducted an intention-to-treat
(ITT) analysis for this review.
All studies used lesionmeasurement as the clinical parameter to as-
sess change; five studies also used pictures of the lesions for clinical
evaluation (Armstrong 2013; Epstein 1994; Hong 1986; Mallery
2014; Piattelli 1999). In 11 RCTs, a complete response was de-
fined as complete disappearance of the lesion (Armstrong 2013;
Epstein 1994; Hong 1986; Li 1999;Mulshine 2004; Nagao 2015;
Papadimitrakopoulou 2008; Piattelli 1999; Sankaranarayan 1997;
Singh 2004; Tsao 2009), lasting at least four weeks in four of them
(Hong 1986;Mulshine 2004; Sankaranarayan 1997; Singh 2004).
For partial response, nine studies used the definition ’greater than
50%reduction’, and one used a slightly different criterion - ’greater
than 30% reduction’ (Li 1999). Three studies defined “stable dis-
ease” as a reduction of less than 50% of the lesion (Hong 1986;
Mulshine 2004; Singh 2004); three studies adopted an otherwise
non-specified “unchanged clinical aspect” (Li 1999; Stich 1988;
Sun 2009); and two studies defined “stable disease” as lesions not
satisfying any other category (Papadimitrakopoulou 2008; Tsao
2009). Eight studies gave similar definitions of “disease progres-
sion” as an increase in the size of the lesion or the appearance of
new lesions (Armstrong 2013; Hong 1986; Li 1999; Mulshine
2004; Papadimitrakopoulou 2008; Singh 2004; Sun 2009; Tsao
2009). One study included the “no response” category, indicat-
ing stable and progressive lesions (Sankaranarayan 1997). Three
studies adopted different categories for clinical evaluation. Stich
1988 used the following: remission, no change, new leukoplakia.
Sun 2009 used positive response (including complete and par-
tial response), stable disease and progressive disease. One study
reported the change in lesion measurement, expressed in mm2
(Mallery 2014). Clinical response was recorded immediately at
the end of treatment in 10 studies (Armstrong 2013; Li 1999;
Mallery 2014; Nagao 2015; Papadimitrakopoulou 2008; Piattelli
1999; Sankaranarayan 1997; Singh 2004; Stich 1988; Tsao 2009),
two weeks after the end of treatment in Epstein 1994 and three
months after the end of treatment in Sun 2009. In two studies, it
was not clear when the reported clinical assessment was recorded
(Hong 1986; Mulshine 2004).
Six studies reported assessment of histological changes (Armstrong
2013; Epstein 1994; Hong 1986; Papadimitrakopoulou 2008;
Singh 2004; Tsao 2009). These studies did not use a unique
histological classification, and the comparison between pre-treat-
ment and post-treatment histological features was highly vari-
able. One study defined histological response as an otherwise
non-specified “reversal” or “improvement” of dysplastic fea-
tures (Papadimitrakopoulou 2008); another adopted a graphical
method for evaluating histological changes (Armstrong 2013).
Stich 1988 reported histological changes in the treatment group
only. In one study, a control biopsy was taken only if development
of cancer was suspected (Sankaranarayan 1997).
Biomarkers evaluated included bcl-2 immunostaining (Piattelli
1999), AgNOR (silver-stained nucleolar organizer region) and
PCNA (proliferation cell nuclear antigen) labelling indexes (Li
1999; Sun 2009), biomarkers of DNA damage in exfoliated cells
and peripheral blood lymphocytes (Li 1999), Neu protein of exfo-
liated cells and serum (Armstrong 2013), epidermal growth factor
receptors (EGFRs) (Li 1999) and p53 and Ki67 (protein; cellular
marker of neoplasia) (Nagao 2015).
Most trials monitored safety of the intervention. Only Li 1999
and Sun 2009 did not appear to measure adverse effects.
Excluded studies
The primary reason for exclusion of each study is given in the
Characteristics of excluded studies table. Many trials were ineli-
gible for more than one reason; however, the more common rea-
sons for exclusion were inappropriate selection of participants,
lack of random allocation and absence of a proper control arm. In
particular, although we found three randomised controlled trials
evaluating surgical interventions (Chee 2013; López-Jornet 2013;
Schwarz 2005), we were unable to include them in the review as
they did not include a no treatment or placebo group.
Risk of bias in included studies
On the basis of criteria used in the critical appraisal of studies, one
study had an overall low risk of bias (Hong 1986).We judged seven
studies as having unclear risk of bias (Epstein 1994;Mallery 2014;
Papadimitrakopoulou 2008; Piattelli 1999; Sankaranarayan 1997;
Singh 2004; Tsao 2009). We considered the remaining studies to
be at high risk of bias (Armstrong 2013; Li 1999; Mulshine 2004;
Nagao 2015; Stich 1988; Sun 2009). See Figure 1 and Figure 2.
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Allocation
We assessed the generation of the randomisation sequence as hav-
ing low risk of bias for six trials and unclear risk for eight trials.
We assessed the concealment of allocation as having low risk of
bias for three trials, at unclear risk for 10 trials and at high risk
for one trial (Armstrong 2013). In Armstrong 2013, the block size
was two.
Blinding
We assessed blinding of participants and personnel, as well as
blinding of outcome assessment, as low risk of bias for 11 trials
and unclear risk for four studies in which not enough information
was provided.
Incomplete outcome data
The reported drop-out rate ranged from 0% (Epstein 1994;
Mallery 2014; Singh 2004) to 32.5% (Armstrong 2013). We as-
sessed 11 trials as having low risk of biaswith regard to attrition bias
because they reported there were no drop-outs, or because drop-
out was not likely to influence findings. We assessed three studies
with high drop-out rates as having high risk of bias (Armstrong
2013; Nagao 2015; Stich 1988).
Selective reporting
Most trials reported important outcomes and were assessed as hav-
ing low risk of bias. Five studies failed to report histological results
(Li 1999; Mulshine 2004; Nagao 2015; Stich 1988; Sun 2009);
we assessed these trials as having high risk of bias for this domain.
Other potential sources of bias
We assessed Epstein 1994, which had discrepant published and
unpublisheddata, alongwith baseline imbalance, as havingunclear
risk of bias for this domain. See Figure 2.
Effects of interventions
See: Summary of findings for the main comparison Vitamin A
or retinoids versus placebo for treating oral leukoplakia; Summary
of findings 2 Systemic beta carotene or carotenoids vs placebo for
treating oral leukoplakia; Summary of findings 3 Non-steroidal
anti-inflammatory drugs (NSAIDs) vs placebo for treating oral
leukoplakia; Summary of findings 4 Herbal extracts vs placebo
for treating oral leukoplakia; Summary of findings 5 Topical
bleomycin vs placebo for treating oral leukoplakia; Summary
of findings 6 Bowman-Birk inhibitor versus placebo for oral
leukoplakia
Vitamin A and retinoids versus placebo
Four studies (one at high, two at unclear and one at low risk of bias)
compared vitamin A and retinoids versus placebo. Three of these
studies evaluated systemic treatment (Hong 1986; Sankaranarayan
1997; Stich 1988), and one evaluated topical treatment (Piattelli
1999).
Oral cancer development
One study reported effects of systemic vitamin A on cancer inci-
dence (Sankaranarayan 1997). Investigators found no evidence of
benefit compared with placebo (risk ratio (RR) 0.11, 95% confi-
dence interval (CI) 0.01 to 2.05; 85 participants) (Analysis 1.1;
Figure 4).
Figure 4. Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.1 Cancer development
Clinical resolution
Five studies reported effects of vitamin A or retinoids on clinical
features of leukoplakia, in particular, on its resolution (Analysis
1.2; Figure 5). In particular, three studies tested systemic treat-
ment (Hong 1986; Sankaranarayan 1997; Stich 1988), but be-
cause heterogeneity was high (I2 = 94%), it was inappropriate to
combine findings in a meta-analysis. Two of the three studies at
high or unclear risk of bias showed some benefit (Sankaranarayan
1997: RR 0.51, 95% 0.37 to 0.71; 85 participants; Stich 1988:
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RR 0.44, 95% CI 0.27 to 0.73; 54 participants), but Hong 1986,
which was at low risk of bias, showed no clear evidence of benefit
(RR 0.92, 95% CI 0.78 to 1.08; 40 participants).
Figure 5. Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.2 Oral lesion not
completely resolved
Hong 1986 provided relapse data: nine out of 16 (56%) partici-
pants who responded to treatment (partially or completely) subse-
quently relapsed (no information was available regarding the two
partial responders from the placebo group). Sankaranarayan 1997
reported that 14 out of 22 (64%) complete responders developed
recurrent lesions (no information was available regarding the three
complete responders in the placebo group).
One study at unclear risk of bias tested topical treatment (nine
participants) and found treatment was not more likely to com-
pletely resolve the lesion than placebo: RR 0.83, 95% CI 0.48 to
1.44 (Piattelli 1999).
In Piattelli 1999, one out of five (20%) participants responding
completely or partially to the experimental treatment relapsed, and
one out of four (25%) participants responding to placebo relapsed.
Improvement of histological features
A single study recorded histological improvement and showed that
improvement in histological features of lesions was more likely
in participants treated with systemic retinoic acid than in those
treated with placebo (RR 0.43, 95% CI 0.24 to 0.76; 39 partici-
pants; Analysis 1.3) (Hong 1986).
Safety
Topical 13-cis-retinoic acid (Piattelli 1999) and 200,000 IU per
week of vitamin A (Stich 1988) produced no adverse effects. Sys-
temic 13-cis-retinoic acid (1 to 2 mg/kg/d) (Hong 1986) caused
adverse effects of varying severity in 79% of participants (see Table
2). Two participants withdrew from Hong 1986 because of severe
conjunctivitis and hypertriglyceridaemia.
Beta carotene or carotenoids versus placebo
Three studies compared systemic beta carotene or carotenoids ver-
sus placebo (Nagao 2015; Sankaranarayan 1997; Singh 2004).
Oral cancer development
Two studies reported the effects of systemic beta carotene on can-
cer incidence (Nagao 2015; Sankaranarayan 1997). Investigators
found no evidence of benefit when compared with placebo (RR
0.71, 95% CI 0.24 to 2.09; 132 participants; I2 = 0%; Analysis
2.1; Figure 6).
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Figure 6. Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.1 Cancer
development
Clinical resolution
Three studies tested effects of systemic beta carotene and
carotenoids on clinical resolution (Nagao 2015; Sankaranarayan
1997; Singh 2004) (Analysis 2.2; Figure 7). Owing to high hetero-
geneity (I2 = 87%), it was not appropriate to combine findings in a
meta-analysis. Two of the individual studies, which were at unclear
risk of bias, found that systemic beta carotene was more effective
thanplacebo for complete resolutionof the lesion (Sankaranarayan
1997: RR0.72, 95%CI 0.58 to 0.90; 89 participants; Singh 2004:
RR 0.61, 95% CI 0.47 to 0.80; 58 participants). The other study,
at high risk of bias, failed to show evidence of benefit (Nagao 2015:
RR 0.95, 95% CI 0.84 to 1.08; 43 participants).
Figure 7. Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.2 Oral lesion
not completely resolved
Sankaranarayan 1997 reported that eight out of 15 (54%) com-
plete responders developed recurrent lesions (no information was
available regarding the three complete responders in the placebo
group).
Improvement of histological features
Evidence of histological improvementwas recordedwhen lycopene
(a carotenoid) was compared with placebo (RR 0.24, 95%CI 0.12
to 0.46; one study; 58 participants; Analysis 2.3) (Singh 2004).
Safety
Systemic treatment with beta-carotene produced no adverse ef-
fects in one study supplementing 10mg/d (Nagao 2015). It caused
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adverse effects of varying severity in 9% of participants in an-
other study supplementing 360 mg/wk (Sankaranarayan 1997).
Researchers reported no adverse effects among participants treated
with systemic lycopene (Singh 2004). See Table 2.
Non-steroidal anti-inflammatory drugs (NSAIDs)
versus placebo
Two studies at unclear risk of bias compared NSAIDs - ketorolac
in Mulshine 2004 and celecoxib in Papadimitrakopoulou 2008 -
versus placebo.
Oral cancer development
Cancer development was among the outcomes reported in
Papadimitrakopoulou 2008. This did not occur in either arm,
probably because of the extremely short duration of the study (12
weeks).
Clinical resolution
Investigators found no evidence of benefit for systemic celecoxib
(Papadimitrakopoulou 2008: RR 0.94, 95% CI 0.83 to 1.08; 46
participants) nor topical ketorolac (Mulshine 2004: RR0.94, 95%
CI 0.81 to 1.10; 56 participants) compared with placebo in terms
of clinical resolution of lesions (Analysis 3.1).
Improvement of histological features
Histological changes were not among the outcomes in the studies
testing NSAIDs.
Safety
In Papadimitrakopoulou 2008, which tested systemic celecoxib,
trialists reported that the treatment was “safe and well tolerated”.
Thirty-two intervention participants reported 56 adverse effects,
and 20 placebo participants reported 20 adverse effects. Minor
adverse events included dizziness, diarrheoa and abdominal pain.
No participants had grade 4 adverse events. Four participants (two
from the placebo group and two from an intervention group) had
grade 3 adverse events. Two people discontinued treatment due to
an adverse event (grade 2 vision abnormality and hypertension in
a participant receiving 400 mgtwice daily of celecoxib and a grade
3 ischemic cerebrovascular accident in a participant receiving 200
mg twice daily of celecoxib.
Ketorolac oral rinse caused adverse effects of varying severity in
29% of participants (see Table 2). One person withdrew from the
trial after the first dose because of mouth pain.
Herbal extracts versus placebo
Four studies compared herbal extracts, in particular, tea com-
ponents (Li 1999; Tsao 2009), a Chinese herbal mixture (Sun
2009) and freeze-dried black raspberry gel (Mallery 2014), versus
placebo.
Oral cancer development
Cancer development was among the outcomes in Tsao 2009; how-
ever, it was not possible to analyse data because trial authors re-
ported the cumulative number of cases, without specifying the
allocation arm.
Clinical resolution
The four studies testing herbal extracts included clinical resolution
among outcomes (Analysis 4.1).
Systemic treatment with green tea extract showed no evidence of
benefit in terms of clinical resolution of leukoplakia when com-
pared with the control in one study at unclear risk of bias (Tsao
2009: RR 0.99, 95% CI 0.86 to 1.14; 39 participants). Li 1999,
which was at high risk of bias, investigated a treatment integrating
systemic (capsules containing 0.38 g of dried mixture of the whole
water extract of green tea, green tea polyphenols and tea pigments)
and topical preparations of mixed tea extract (mixed tea in glycerin
at the concentration of 10%), but was not able to demonstrate
benefit when compared with placebo in terms of clinical resolu-
tion (RR 1.00, 95% CI 0.94 to 1.07; 59 participants).
In one study investigating effects of a Chinese herbal mixture, it
was not possible to extract data on clinical resolution (Sun 2009).
One topical herbal treatment (freeze-dried black raspberries)
showed no evidence of benefit when compared with placebo in a
study that was at unclear risk of bias (Mallery 2014: RR 4.13, 95%
CI 0.21 to 80.91; 40 participants). Among participants who did
respond to such treatment, six of 22 (32%) in the treatment arm
and seven of 17 (41%) in the placebo arm had visible evidence of
lesion recurrence at former treatment sites at three months post
trial follow-up (Mallery 2014).
Improvement of histological features
In two studies reporting histological changes, neither active treat-
ment (topical freeze-dried black raspberries and systemic green
tea extract) showed benefit when compared with placebo (Mallery
2014: RR 0.97, 95% CI 0.58 to 1.60; Tsao 2009: RR 0.86, 95%
CI 0.66 to 1.13; Analysis 4.2).
Safety
People undergoing treatment with green tea reported very high
frequency (93%) of adverse effects of varying severity in one study (
Tsao 2009). Adverse effectswere notmentioned inLi 1999. Freeze-
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dried black raspberry gel caused no adverse effects (Mallery 2014).
Sun 2009 stated, “drug toxicity was not monitored in the clinical
trial”. See Table 2.
Topical bleomycin versus placebo
Topical bleomycin was tested against placebo in a single small
study at unclear risk of bias that included 22 participants (Epstein
1994). Following post-treatment biopsy, seven participants in the
placebo group were crossed over to receive the active intervention.
An ITT analysis was conducted for outcomes measured after post-
treatment biopsy.
Mean follow-up from the end of the study was 15 months for
group A and 22 months for group B.
Oral cancer development
The trial found no evidence of benefit of topical bleomycin com-
pared with placebo in reducing cancer development among par-
ticipants affected by leukoplakia (RR 3.00, 95%CI 0.32 to 27.83;
20 participants; Analysis 5.1).
Clinical resolution
Topical bleomycin showed no benefit for clinical resolution when
compared with placebo: RR 0.55, 95% CI 0.29 to 1.04. In ad-
dition, among participants for whom follow-up information was
available, two out of four (50%) participants with a complete re-
sponse relapsed and one out of two (50%) participants with a par-
tial response relapsed (Analysis 5.2).
Improvement of histological features
Epstein 1994 reported histological changes, showing no benefit of
topical bleomycin when compared with placebo: RR 0.49, 95%
CI 0.22 to 1.10 (Analysis 5.3).
Safety
Topical bleomycin caused adverse effects of varying severity in
100% of participants (see Table 2). Participants in the bleomycin
group developed erythema with erosion. Erythema developed in
the placebo group; 60% of the bleomycin group reported discom-
fort but did not require analgesics. The trial found no evidence of
systemic toxicity.
Bowman-Birk Inhibitor versus placebo
A single study tested the Bowman-Birk inhibitor against placebo
(Armstrong 2013).
Oral cancer development
Cancer development was not among the outcomes of the study
testing the Bowman-Birk inhibitor.
Clinical resolution
The topical Bowman-Birk inhibitor showed no benefit for clinical
resolution when compared with placebo: RR 1.00, 95% CI 0.91
to 1.09 (Analysis 6.1).
Improvement of histological features
Data on histological changes fromArmstrong 2013 were not avail-
able for analysis, but study authors reported no statistically signif-
icant differences in histological changes between study arms.
Safety
The Bowman-Birk inhibitor caused adverse effects of varying
severity in 49% of participants (see Table 2).
Sensitivity analysis
We did not undertake sensitivity analysis excluding studies at high
or unclear risk of bias, as the only study at low risk of bias was not
included in a meta-analysis (Hong 1986).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia
Patient or population: people with oral leukoplakia
Intervention: systemic beta carotene
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with beta carotene
or carotenoids
Cancer development at
24 months f rom start
of treatment (treatment
lasted 12 months)
108 per 1000 79 per 1000
(26 to 238)
RR 0.73
(0.24 to 2.20)
132
(2 RCTs)
⊕⊕©©
very low1
Clinical resolut ion (not
completely resolved) at
5 to 12 months
The 3 studies could not be combined in meta-analysis. 2 found benef it f or systemic beta carotene, and 1 did not
Histological changes
(not improved)
at 5 months (treatment
lasted 3 months)
833 per 1000 200 per 1000
(100 to 383)
RR 0.24 (0.12 to 0.46) 58
(1 RCT)
⊕⊕©©
low2
Safety of the interven-
t ion at 5 to 12 months
Systemic beta carotene did not cause any adverse ef fects in 1 study supplementing 10 mg/ d, and caused adverse ef fects of varying severity in 9% of
part icipants in another study supplementing 360 mg/ wk
No adverse ef fects were reported by part icipants treated with systemic lycopene in one study
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI)
CI = conf idence interval; RR = risk rat io; vs = versus; d = day; wk = week
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
∗ From event rate in control group
aDowngraded 3 levels for unclear or high risk of bias and serious imprecision
bDowngraded 2 levels as single small study at unclear risk of bias
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NSAIDs vs placebo for treating oral leukoplakia
Patient or population: people with oral leukoplakia
Intervention: NSAIDs
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with NSAIDs
Cancer development Not measured
Clinical resolut ion (not
completely resolved) at
3 months
1 study evaluated systemic treatment and 1 evaluated topical treatment. Neither found benef it f or NSAIDs
Histological changes
(not improved)
Not measured
Safety of the interven-
t ion
over 3 months
Systemic celecoxib (1 study) - 32 intervent ion part icipants reported 56 adverse ef fects and 20 placebo part icipants in the placebo group reported
20 adverse ef fects. M inor adverse events included dizziness, diarrheoa and abdominal pain. 4 part icipants (2 f rom the placebo group and 2 f rom
an intervent ion group) had grade 3 adverse events. 2 part icipants permanently discont inued treatment owing to an adverse event (grade 2 vision
abnormality and hypertension in a part icipant receiving 400 mg twice daily of celecoxib and a grade 3 ischaemic cerebrovascular accident in a
part icipant receiving 200 mg twice daily of celecoxib)
Ketorolac oral rinse (1 study) caused adverse ef fects of varying severity in 29% of part icipants
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI = conf idence interval; RR = risk rat io; vs = versus
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
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Herbal extracts vs placebo for treating oral leukoplakia
Patient or population: people with oral leukoplakia
Intervention: herbal extracts - tea components; a Chinese herbal m ixture; curcumin chewing gum; f reeze-dried black raspberry gel
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with herbal ex-
tracts
Cancer development Not measured
Clinical resolut ion (not
completely resolved) at
3 to 6 months
3 studies (1 of f reeze-dried black raspberry gel, 1 of green tea extract capsules and 1 of mixed tea treatment) did not f ind evidence of benef it f or the
intervent ion
Histological changes
(not improved) at 3
months
2 studies (1 of green tea extract capsules and 1 of f reeze-dried raspberry gel) did not f ind evidence of benef it f rom these intervent ions
Safety of the interven-
t ion up to 3 months
3 studies measured adverse ef fects: green tea extract capsules caused high f requency (93%) of adverse ef fects of varying severity in 1 study; the
mixed tea treatment study did not mention adverse ef fects; f reeze-dried black raspberry gel did not cause any adverse ef fects
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI = conf idence interval; RR = risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
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Topical bleomycin vs placebo for treating oral leukoplakia
Patient or population: people with oral leukoplakia
Intervention: topical bleomycin
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with topical
bleomycin
Cancer development up
to 7 years
83 per 1000 250 per 1000
(27 to 1000)
RR 3.00
(0.32 to 27.83)
20
(1 RCT)
⊕©©©
very lowa
Clinical resolut ion (not
completely resolved)
at 3 months
917 per 1000 504 per 1000 (266 to
954)
RR 0.55 (0.29 to 1.04) 22
(1 RCT)
⊕©©©
very lowa
Histological changes
(not improved) at 3
months
818 per 1000 401 per 1000 (180 to
900)
RR 0.49 (0.22 to 1.10) 21
(1 RCT)
⊕©©©
very lowa
Safety of the interven-
t ion up to 3 months
‘‘All pat ients in the bleomycin group developed erythema with erosion by the end of the applicat ions, whereas erythema developed in the placebo
group. Discomfort was reported by 60% of the bleomycin group, but analgesics were not required. Taste of the topical applicat ion as well-tolerated.
There was no observed systemic toxicity in the pat ient groups’’
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI)
CI = conf idence interval; RR = risk rat io; vs = versus
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
∗ From event rate in control group24
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aDowngraded 3 levels as a single small study at unclear risk of bias with imprecise result
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Bowman-Birk inhibitor vs placebo for treating oral leukoplakia
Patient or population: people with oral leukoplakia
Intervention: Bowman-Birk inhibitor
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Bowman-Birk
inhibitor
Cancer development Not measured
Clinical resolut ion (not
completely resolved) at
6 months
957 per 1000 957 per 1000
(871 to 1000)
RR 1.00 (0.91 to 1.09) 21
(1 RCT)
⊕⊕©©
lowa
Histological changes
(not improved) at 6
months
Not measured
Safety of the interven-
t ion up to 6 months
Trial authors reported that there were no signif icant adverse ef fects. 33 part icipants in the intervent ion group reported 75 adverse ef fects. 25
part icipants in the placebo group reported 63 adverse ef fects
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI = conf idence interval; RR = risk rat io; vs = versus
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
∗ From event rate in control group
aDowngraded 2 levels as a single small study at high risk of bias2
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D I S C U S S I O N
Leukoplakia is themost common potentially malignant oral disor-
der. Although rates of oral ccancer development may vary among
studies, probably as the result of differences in diagnostic criteria
for leukoplakia and follow-up intervals, themorbidity andmortal-
ity associated with oral cancer suggest that leukoplakia is a relevant
health issue for affected individuals. Yet, of the 14 studies included
in the present review, none evaluated a surgical intervention nor
the effect of habit cessation, and only three studies provided data
on the effects of a medical or complementary treatment on cancer
incidence.
Summary of main results
At present, there is no evidence that any of the medical or com-
plementary treatments studied for people with leukoplakia can
reduce the likelihood of oral cancer development. It should be
noted that this conclusion is based on only three studies, namely,
those testing systemic vitamin A, systemic beta carotene and topi-
cal bleomycin. These studies, which were at high or unclear risk of
bias, included relatively few participants and had limited follow-
up. Overall, the quality of the evidence was very low.
Clinical change, in terms of variation in lesion size, was an out-
come reported by all studies, although esearchers used different
methods of measurement. Some single studies suggested effec-
tiveness of some proposed treatments, namely, vitamin A, beta
carotene and lycopene, in achieving complete clinical resolution
of lesions more often than placebo (Sankaranarayan 1997; Singh
2004; Stich 1988). Similarly, single studies showed that vitamin
A and lycopene provided some benefit in terms of improvement
in histological features (Hong 1986; Singh 2004).
Leukoplakias generally are not associated with significant signs
and symptoms, and the risk of developing cancer is relatively low
(i.e. many patients with leukoplakia receive treatment that is not
necessary). Therefore, proposed treatments should have minimal
propensity for adverse effects. The proportion of participants re-
porting adverse effects varied between 0 and 100% in the ac-
tive arms of the included trials, and between 0 and 90% in the
placebo arms; however adverse effects were always more common
in the study group than in the control group (see Table 2). It
seems likely that interventions were well accepted by participants
because drop-out rates were similar between treatment and con-
trol groups (see Table 3); however, follow-up may not have been
long enough to permit this assessment. Adverse effects caused
participants to withdraw in three studies: when systemic 13-cis-
retinoic acid induced severe conjunctivitis and hypertriglyceri-
daemia (Hong 1986); when intolerable mouth pain followed the
initial ketorolac mouthrinse (Mulshine 2004); and in two partic-
ipants treated with celecoxib, because of vision abnormality and
hypertension in one, and ischaemic cerebrovascular accident in
another (Papadimitrakopoulou 2008).
Overall completeness and applicability of
evidence
Less than half (33% to 42%) of people with leukoplakia who de-
velop oral cancer do so within two years of diagnosis (Lind 1987;
Silverman 1984), and the incidence of oral cancer increases with
the duration of follow-up (Shiu 2000). Therefore, to properly test
the effects of treatments on cancer incidence, it would be neces-
sary to plan studies with large groups of participants and a long
follow-up period - ideally, multi-centre randomised controlled tri-
als (RCTs) assessing outcomes at 10 years. As the duration of the
studies included in this review was less than 12 months in all but
four studies (Epstein 1994; Nagao 2015; Sankaranarayan 1997;
Tsao 2009), cancer incidence rates are likely to be underestimated.
Indeed, most of the studies did not include cancer incidence as an
endpoint, but rather employed outcomes that assessed clinical or
histological markers or both. Although easier to perform, studies
using such outcomes pose a double problem: first, there is little ev-
idence of the predictive value of many of those outcomes; second,
they are difficult to compare. In addition, widespread outcomes,
such as dysplasia grade, may be affected by high inter-observer and
even intra-observer variation (Abbey 1995; Karabulut 1995).
It is noteworthy that, although surgery is the first choice in leuko-
plakia management for many clinicians, there is an absence of
RCTs comparing the effects of surgical excision versus no treat-
ment or placebo (Marley 1998). The only data available are from
observational studies comparing rates of cancer incidence in peo-
ple who did or did not undergo surgical treatment for oral leuko-
plakias. Such studies have differences in diagnostic and inclusion
criteria, follow-up interval, participant characteristics and surgi-
cal techniques employed (scalpel, laser, cryotherapy). They show
highly variable results and sometimes are conflicting in their con-
clusions (Saito 2001; Schepman 1998). In addition, on the basis
of animal and clinical studies, it has been speculated that surgery
itself might act to promote carcinogenesis in pre-malignant oral
lesions (Holmstrup 2009). Trials evaluating interventions directed
against risk factors (e.g. smoking) are also missing.
The applicability of results of two of the included studies
(Sankaranarayan 1997; Stich 1988) should be considered in the
context of their different risk factor profile as the participants were
all betel quid chewers, a risk factor uncommon in individuals from
geographical areas outside South Asia.
Leukoplakias with different histological or molecular characteris-
tics may have different risks of transforming into cancer. However,
the value of predictive factors proposed so far in the literature re-
quires sound confirmatory data. The presence of epithelial dyspla-
sia may be predictive of a transformation to oral cancer and the
risk of cancer may increase with the severity of dysplastic changes
(Lumerman 1995; Schepman 1998; Warnakulasuriya 2011), al-
though this hypothesis has been recently challenged (Holmstrup
2006). Unfortunately, the available data did not allow us to per-
form a subgroup analysis of lesions with and without dysplasia,
thus it is not possible to establish whether any particular treat-
27Interventions for treating oral leukoplakia to prevent oral cancer (Review)
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ment may be more indicated in the presence of dysplasia of differ-
ent severity. Many different molecular biomarkers have been pro-
posed, but no single marker or battery of markers seems predictive
enough to be implemented during clinical care.
Quality of the evidence
Of the studies included in the present review, we judged one as
having low risk of bias, six asunclear risk of bias and seven ashigh
risk of bias. Although these studies were randomised trials, in-
formation about randomisation methods was missing or incom-
plete in most studies. In particular, methods used for random se-
quence generation were unclear in eight out of 15 studies, and
details on allocation concealment were missing in 10 out of 15
studies. The body of evidence for cancer incidence comprises three
studies investigating three different treatments: vitamin A, beta
carotene and topical bleomycin. We assessed these studies as hav-
ing very low quality according to GRADE (Grades of Recommen-
dation, Assessment, Development and Evaluation) assessment cri-
teria (see Summary of findings for themain comparison; Summary
of findings 2; Summary of findings 5). Thus, the quality and the
number of included trials, often with short follow-up times, sug-
gest cautious interpretation of results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No randomised controlled trials (RCTs) on surgical treatment for
people who have oral leukoplakia have included placebo and ac-
tive treatment arms. Nor have RCTs examined risk factor cessation
(e.g. smoking). Therefore, the effectiveness of these interventions
cannot be reliably assessed. None of the medical and complemen-
tary treatments studied (vitamin A, beta carotene, bleomycin) has
been shown to be effective in preventing cancer onset in people
with leukoplakia, and, despite the findings of some studies that
vitamin A or beta carotene may be effective in reducing or even
resolving oral leukoplakia in the short term, the risk of subsequent
relapse seems high.
Implications for research
Although surgery remains the treatment option favoured by most
clinicians, the effectiveness of surgery comparedwith no treatment
(“wait and see”) has not been assessed in RCTs for prevention of
cancer development in peoplewith leukoplakia. Research is needed
to assess surgical treatment of patients with leukoplakia and to
evaluate effects of risk factor cessation in people with leukoplakia.
Larger, better conducted trials of longer duration are required to
properly evaluate the effects of any treatment on malignant trans-
formation rates, which should be considered the primary outcome
when effectiveness of treatments for leukoplakia is tested.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Armstrong 2013
Methods Study design: RCT, parallel-group, 2 arms
Conducted in USA
Number of centres: 8
Recruitment period: May 1999 to September 2009
Funding source: Central Soya Company, NIH
Study duration: 6 months
Participants Inclusion criteria
At least 18 years old, with histologically proven oral leukoplakia and/or erythroplakia, ca-
pable of being measured bi-dimensionally; pre-menopausal and perimenopausal women
were required to agree to use adequate birth control methods and to have a negative
pregnancy test. At completion of the 4-week run-in phase of the study, during which
participants self administered the placebo compound, 75% compliance with administra-
tion of drug measured by counting unused drug packets was required for continuation
in the study
If recent (within 3months) histological analysis had not been documented with review of
biopsy, 3-mm punch biopsy of representative lesions was conducted after measurement
and photodocumentation of the lesion
Exclusion criteria
Use of systemic or topical oral steroids within 3 months, currently pregnant or lactating,
presence of head and neck cancer (including in situ disease), history of such within 2
years, retinoid or beta carotene therapy for any reason within 2 years or beta carotene
capsules of any size within 6 months (participants were allowed up to 2 multi-vitamins
per day), participation in another randomised clinical trial within 6 months
Histological criteria for leukoplakia
Not reported
132 people randomised: 48/132 (36%) reported use of beer, wine or liquor, whereas 56/
132 (42%) did not answer questions on alcohol consumption; 28/132 (21%) reported
using tobacco (viz., cigarettes, cigars, pipe, oral use), whereas 66/132 (50%) did not
answer questions on tobacco use. Percentage of dysplastic lesions was not reported
89 people completed the study: 32/89 females, mean age 60.7 (range 29 to 82), ethnic
group 69/89 white, tobacco users 20/89 (but 40/89 unknown), alcohol users 35/89 (but
34/89 unknown)
Group A: randomised 67; 43 completed the study. 41 available for histological analysis
Group B: randomised 65; 46 completed the study. 46 available for histological analysis
Interventions Group A: 3 grams Bowman-Birk Inhibitor concentrate twice a day for 6 months
Group B: 3 grams placebo (corn tortilla mix) twice a day for 6 months
Compliance control: not reported
Outcomes Clinical response
The primary end point was relative per cent change in total lesion area after 6 months in
the study, and the percentage of participants showing a clinical response on that measure.
A complete response was declared if the relative per cent change in total lesion area was
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Armstrong 2013 (Continued)
minus 100%. A partial response was a relative per cent decrease in total lesion area of
50% or more, without a complete response. Disease progression was a relative per cent
increase in total lesion area of at least 50%. Remaining cases were declared to be stable
disease
A secondary clinical response measure was change in clinical impression from pho-
tographs of lesions based on blinded, comparative judgements of pairs of photographs
of the same lesion at baseline and at 6 months on the study using a 7-point scale
Histological response
A single, experienced pathologist compared pre-treatment and post-treatment pairs of
tissue specimens. The pathologist was blinded to study arm assignment (drug or placebo)
, but not to time point of the specimen. For each specimen, the pathologist marked a
continuum to indicate the degree of tissue abnormality. The continuum was 140 mm
long, and was anchored by the word ‘normal’ on the left and ‘malignant’ on the right. The
distance from the left edge of the continuum to the pathologist’s mark, in millimetres,
was determined. For analyses, a score was determined by subtracting the pre-treatment
value from the 6-month value. The central pathologist also made a direct comparison of
pre-treatment and post-treatment specimens, marking a 170-mm continuum anchored
on the left by “posttreatment shows no dysplasia in comparison with pretreatment,” and
on the right by “posttreatment shows greater dysplasia than pretreatment”. The centre
of the continuum was labelled, “pretreatment and posttreatment show no difference.”
The reviewer’s mark was coded as the distance from the left edge, in millimetres. On this
measure, low scores denote improvement over time, a score of 85 denotes no change and
a value greater than 85 indicates histological worsening
Other outcomes included changes in buccal cell and serum Neu protein, buccal cell
protease activity, adverse events
Notes Initially it was required that the total lesion area estimated at baseline be at least 100 mm
2, but later this requirement was relaxed to facilitate accrual
Early in the study, participants on the drug arm who showed a partial or complete
response at 6 months were allowed to continue treatment for an additional 12 months
(total 18 months) with final follow-up at 21 months. However, because of the limited
supply of drugs, the protocol was soon modified to limit treatment to 6 months
Bowman-Birk inhibitor concentrate was initially produced and supplied by Central Soya
Company, but was later supplied by the NIH/National Cancer Institute/Division of
Cancer Prevention pharmacy
Both treatment and placebo groups showed a statistically significant decrease in total
lesion area
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Indepen-
dent randomisation schedules were created
for each performance centre (so study-arm
assignment would not be confounded with
geography). For those centres expected to
accrue at a faster rate, the randomisation
schedule incorporated a block size of 4. A
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block size of 2 was used for centres with
lighter accrual goals”
Allocation concealment (selection bias) High risk Comment: block size 2
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: high number of lost partici-
pants: 43/132 (32.5%)
Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias identi-
fied
Epstein 1994
Methods Study design: RCT, parallel-group, 2 arms
Conducted in Canada
Number of centres: 1
Recruitment period: unspecified
Funding source: unspecified
Study duration: 2 weeks for treatment plus open follow-up
Participants Inclusion criteria
Patients older than 18 years with clinically visible leukoplakia and pathological diagnosis
of the lesion
Exclusion criteria
Pregnant women, women of childbearing age in whom contraceptionwas not confirmed,
cases of carcinoma in situ, invasive SCC and lesions identified as inflammatory in nature
Histological criteria for leukoplakia
Histological diagnosis of hyperkeratosis or acanthosis with or without dysplasia. 22% of
the lesions were dysplastic
22 participants randomised: 12/22 females, mean age 56.6 (range 25 to 79), ethnic
group not reported, 14 (63%) tobacco users, 10 (45%) alcohol users. Leukoplakia was
significantly larger in the placebo group (320 mm2) compared with the test group (76
mm2) at randomisation
Group A: randomised 10; 10 completed the study
Group B: randomised 12; 12 completed the study (12 analysed clinically, 11 analysed
histologically)
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Interventions Group A: 1 daily topical application of 1% w/v bleomycin in dimethylsulphoxide for
14 days
Group B: 1 daily topical application of placebo (dimethylsulphoxide only) for 14 days
Compliance control: yes
Outcomes Cancer incidence
Clinical response
Measurement of the lesion before the start of treatment and weekly during treatment:
(1) complete response was defined as no clinical and histological evidence of leukoplakia,
(2) partial response was defined as a greater than 50% reduction in the size of the lesion
or elimination of dysplasia. Data from the first follow-up visit (2 weeks from the end of
treatment) are included in the meta-analysis
Histological response
Histological grading before the start of treatment and 4 weeks after treatment
Other outcomes: assessment of oral burning and pain during application, between
applications and with eating. Adverse effects
Notes After the post-treatment biopsy (4 weeks after treatment), 7 participants in the placebo
groupwere crossed over to receive 1%w/vbleomycin indimethylsulphoxide.We received
unpublished data onmalignant transformation and based our ITT analysis on those data
Mean follow-up from the end of the study: 15 months (group A) and 22 months (group
B)
Based our analyses on raw data supplied by trial authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomised to the
drug or placebo arm by the department of
Pharmacy, with the use of a table of random
numbers”
Allocation concealment (selection bias) Low risk Quote: “patients were randomised to the
drug or placebo arm by the department of
Pharmacy”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing data with the exception of 1/12
(8.3%) histological outcome in the control
group
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Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Unclear risk Some areas of concern: discrepancies be-
tween published and raw data; baseline im-
balance in lesion size; cross-over to inter-
vention of more than half of participants in
the placebo group
Hong 1986
Methods Study design: RCT, parallel-group, 2 arms
Conducted in USA
Number of centres: unspecified
Recruitment period: unspecified
Funding source: supported by a grant from Hoffmann-La Roche and in part by a grant
from the National Cancer Institute
Study duration: 9 months (3 months of treatment plus 6 months of follow-up)
Participants Inclusion criteria
Histologically confirmed oral leukoplakia
Exclusion criteria
Women with reproductive capacity, persons taking megadoses of vitamin A (> 25,000
USP units/d), patients who had an oral cancer within the 2 years preceding the study
Histological criteria for leukoplakia
Not reported
44 participants randomised:
• 13 females
• 9 participants < 50 years old; 29 participants 50 to 69 years; 6 participants > 70
years
• Ethnic group not reported
• 9 (20%) tobacco users, 11 (25%) alcohol users, 20 (45%) tobacco + alcohol users
• 27% of lesions were dysplastic
Group A: randomised 24; 22 completed the study (analysed 22 clinically, 21 histologi-
cally)
Group B: randomised 20; 18 completed the study
Interventions Group A: capsules of 13-cis-retinoic acid (1 to 2 mg/kg/d) for 3 months
Group B: capsules of placebo for 3 months
Compliance control: yes, pill counts at each visit
Outcomes Clinical response
Measurement of the lesion, colour photography performed before the start of treatment
and every 2 to 3 weeks during treatment: (1) complete response was defined as no
clinical evidence of leukoplakia for at least 4 weeks; (2) partial response was defined as
a greater than 50% reduction in the product of the longest diameters of the lesion; (3)
a response was classified as stable when the decrease in lesion size was less than 50%;
(4) disease progression was defined as an unequivocal increase in the size of any lesion
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during treatment or as the appearance of a new lesion
Histological response
Histological grading was done before the start of treatment and upon its completion.
Histological grading included (1) atypical hyperplasia; (2) mild dysplasia; (3) moderate
dysplasia; (4) severe dysplasia or carcinoma in situ
Other outcomes included laboratory analysis, including fasting serum triglycerides and
liver function testing
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the randomisation code was com-
puter-generated”
Allocation concealment (selection bias) Low risk Quote: “randomisation was performed by
the pharmacy” and “The code for treat-
ment assignment was broken after the pa-
tients had completed the full nine months
of study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither the patient nor the physi-
cian was aware of which treatment was as-
signed”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “neither the patient nor the physi-
cian was aware of which treatment was as-
signed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups and not likely
to have a clinically relevant impact on the
intervention effect estimate: 4/44 (9%)
Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias iden-
tified
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Li 1999
Methods Study design: RCT, parallel-group, 2 arms
Conducted in China
Number of centres: 1
Recruitment period: unspecified
Funding source: supported by a grant from the Chinese National Natural Science
Foundation
Study duration: 6 months
Participants Inclusion criteria
Not specified
Exclusion criteria
Patients with severe dysplasia
Histological criteria for leukoplakia
Not reported
64 participants randomised: 24 females, mean age 54.5 (range 23 to 78), ethnic group
not reported, 46 (71.9%) tobacco users. 20% of lesions were dysplastic
Group A: randomised 32, 29 completed the study
Group B: randomised 32, 30 completed the study
Interventions Group A: systemic (capsules) and topical (paint) mixed tea (3 grams/d and 3 paintings/
d) for 6 months
Group B: systemic (capsules) and topical (paint) placebo for 6 months
Compliance control: not reported
Outcomes Clinical response
Size and number of lesions of each participant were recorded at baseline and at the end
of the trial: (1) complete regression was defined as complete disappearance of the lesion;
(2) partial regression was defined as a 30% or greater reduction in the size of a single
lesion or in the sum of sizes of multiple lesions; (3) lesions with no change in size were
recorded as no change; (4) deterioration referred to the occurrence of new lesions
Histological response
Oral biopsies were conducted at the beginning and at the end of the trial. Besides routine
histopathological examination, lesional tissue investigations included also silver-stained
nucleolar organizer regions (AgNOR), proliferation cell nuclear antigen (PCNA) and
epidermal growth factor receptor (EGFR) analysis
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Personal communication: random se-
quence based on random number table.
Randomisation stratified for presence of
dysplasia
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups and not likely
to have a clinically relevant impact on the
intervention effect estimate: 5/64 (7.8%)
Selective reporting (reporting bias) High risk Comment: missing histological assessment
of lesions at the end of the study
Other bias Low risk Comment: no other sources of bias iden-
tified
Mallery 2014
Methods Study design: RCT, parallel-group, 2 arms
Conducted in US
Number of centres: 3
Recruitment period: unspecified
Funding source: supported by NIH NCI RC2 CA148099. S.R.Mallery has ownership
interest (including patents) in BRB gel patent
Study duration: 6 months (12 weeks plus 3 months of follow-up)
Participants Inclusion criteria
Microscopically confirmed pre-malignant oral epithelial lesions, no use of tobacco prod-
ucts for 6 weeks before and during the 3-month study, no previous history of cancer
(except for basal cell carcinoma of the skin). Participants screened before entrance into
and during (10 to 12 days recall intervals) the trial for no tobacco use compliance via
unannounced saliva testing for nicotine (NicAlert, JANT Pharmacal Corporation)
Exclusion criteria
Previous or current history of non-basal cell cancer, use of tobacco products, and either
a microscopic diagnosis of no pre-malignant change or OSCC in the pre-trial biopsy
Histological criteria for leukoplakia
Not reported
40 participants randomised: 22 females, mean age 60.15 (range 32 to 78), ethnic group
not reported, 24 (60%) former smokers. 72.5% of lesions were dysplastic: 63% (14/22)
in Group A and 83% (15/18) in Group B
Group A: randomised 22, 22 completed the study. 21 available for post-trial examination
Group B: randomised 18, 18 completed the study. 17 available for post-trial examination
40Interventions for treating oral leukoplakia to prevent oral cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Interventions Group A: topical application of a bioadhesive gel that contained 10% w/w freeze-dried
black raspberries (0.5 g, q.i.d. for 12 weeks)
Group B: topical application of a bioadhesive placebo gel that contained 10% w/w
sucrose and food colorants (0.5 g, q.i.d. for 12 weeks)
Compliance control: yes
Outcomes Clinical response
Clinical photographs of lesions were taken with a calibrated measuring device (Puritan)
placed parallel to the long axis of the lesion. Acquired clinical images were analysed using
ImagePro 6.2 software (Media Cybernetics). Lesional sizes were normalised to square
millimetres (mm2) according to the following formula: lesional size mm2 = pixels of
lesional area × 100/(pixels of 1 centimetre unit on the calibration device in the same
image). The remaining lesional area after the initial biopsy and before gel treatment was
the pre-treatment size. Post-treatment lesional size was the residual lesional area after 3
months of gel treatment and just before the final biopsy
Histological response
Histological grading was done before the start of treatment and upon its completion. A
0 to 8 grade scale (0 = normal with or without hyperkeratosis, 1 = atypia with crisply
defined clinical margins, 2 = mild dysplasia, 3 = mild-moderate dysplasia, 4 = moderate
dysplasia, 5 = moderate-severe dysplasia, 6 = severe dysplasia, 7 = carcinoma in situ, 8 =
invasive SCC) was used to rank light microscopic diagnoses
Notes 30participants hadOIN lesions (16 inBRB - 72.7%and14 in placebo - 77.7%) thatwere
recalcitrant to surgery and had recurredmultiple times (2 to 8) at the same site before trial
participation. 12 Group A and 3 Group B participants had a history of multiple lesions
dispersed throughout the mouth, consistent with a diagnosis of proliferative verrucous
leukoplakia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All participating oral pathologists,
surgeons, and patients were blinded to the
patients’ gel assignments”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All participating oral pathologists,
surgeons, and patients were blinded to the
patients’ gel assignments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data. All randomised partici-
pants included in analysis of results
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Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias identi-
fied
Mulshine 2004
Methods Study design: RCT, parallel-group, 2 arms
Conducted in USA
Number of centres: 3
Recruitment period: unspecified
Funding source: supported by a grant from the National Cancer Institute Specialized
Programs of Reasearch Excellence (SPORE) Program
Study duration: 4 months (90 days of treatment plus 1 month of follow-up)
Participants Inclusion criteria
Patients with bi-dimensionally measurable leukoplakia of the oral cavity or of the
oropharynx. In cases of previous oral cancer diagnosis, individuals had to be free from
disease for at least 3 months, excellent performance status, general good health
Exclusion criteria
Hypersensitivity to aspirin, lidocaine, NSAIDs, retinoids. Use of antibiotics, steroids,
NSAIDs, aspirin, probenecid, antihistamines for > 10 consecutive days, or any immuno-
suppressants, anticoagulants, dilantin, lithium, methotrexate, phenothiazines or drugs
that could compromise test product safety during the 30 days immediately preceding the
first treatment visit, debilitating oral conditions requiring extensive dental procedures or
conditions interfering with compliance. Respiratory or cardiovascular problems
Histological criteria for leukoplakia
Not reported
57 participants randomised: 19 females; age not reported; ethnic group: non-white par-
ticipants: 6/57, white participants: 51/57; 48/56 (86%) smokers, 40/56 (71%) alcohol
users. Percentage of dysplastic lesions not reported
Group A: randomised 38, 37 completed the study
Group B: randomised 19, 19 completed the study
Interventions Group A: mouthwash with ketorolac 0.1%, twice a day, for 90 days
Group B: mouthwash with placebo, twice a day, for 90 days
Compliance control: yes
Outcomes Clinical response
Measurement of the lesion. (1) Complete response was defined as no clinical evidence
of leukoplakia for at least 30 days from inception of treatment. (2) Partial response was
defined as a greater than 50% reduction in the product of the longest diameters of a
single lesion (in the sum of these figures for all lesions, in the setting of multiple lesions)
for at least 30 days. (3) A response was classified as stable when the decrease in lesion
size was less than 50%. (4) Disease progression was defined as an unequivocal increase
in size greater than 10%, or as the appearance of a new lesion. Clinical evaluations were
made at study entry, monthly during the intervention and 1 month after cessation of
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Mulshine 2004 (Continued)
study drugs
Histological response
Histological grading was done before the start of treatment and upon its completion
Notes Nine of the 56 participants who completed the study had an oropharyngeal leukoplakia
(6 in Group A and 3 in Group B)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data are balanced in
numbers across intervention groups and are
not likely to have a clinically relevant im-
pact on the intervention effect estimate 1/
57 (1.7%)
Selective reporting (reporting bias) High risk Comment: data on histological modifica-
tions reported only partially
Other bias Low risk Comment: no other sources of bias identi-
fied
Nagao 2015
Methods Study design: RCT, parallel-group, 2 arms
Conducted in Japan
Number of centres: 3
Recruitment period: not reported
Funding source: supported by Butterfield Award of the Sasakawa Foundation GB and
DSM Nutrition Japan
Study duration: 1 year plus open follow-up
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Participants Inclusion criteria
Patients with leukoplakia who had never smoked or were ex-smokers
Exclusion criteria
Current smokers or ex-smokers within 3 months of cessation
Histological criteria for leukoplakia
Not reported
46 participants randomised: 21 females; median age 65 (range 38 to 80 years); ethnic
group: all Japanese; never smoked or ex-smokers; alcohol users not reported Percentage
of dysplastic lesions not reported
Group A: randomised 23, 16 completed the study
Group B: randomised 23, 17 completed the study
Interventions Group A: 10 mg/d of beta carotene and 500 mg/d of vitamin C for 1 year
Group B: 50 mg/d of vitamin C for 1 year
Compliance control: not reported
Outcomes Cancer incidence
Study authors provided unpublished cancer incidence after a median follow-up of 86
months. Trial authors intended to exclude from the analysis any cases that progressed
to oral cancer within 6 months of the start of the study, but there were no cancer cases
within 6 months
Clinical response
Complete remission, partial remission, no change, disease progression
Histological response
Severity degree of epithelial dysplasia
p53 and Ki67 expression
Serum levels of antioxidant micronutrients
Notes Follow-up since the end of treatment: 60 months for clinical response, 86 months for
cancer incidence
2 participants in the experimental arm and 1 in the control arm did not receive allocated
interventions. During intervention, 5 participants in the experimental arm and 5 in the
control arm dropped out. Among these, 3 in the experimental arm and 4 in the control
arm returned for follow-up at the close of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random allocation was performed
[...] with stratification by blocking ran-
domisation according to presence or ab-
sence of dysplasia”
Allocation concealment (selection bias) Low risk Quote: “a trial coordinator not involved in
the routine care of patients generated the
allocation sequence and enrolled partici-
pants. The central randomisation by num-
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bered containers was used for allocation
concealment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk High number of drop-outs (stopping treat-
ment) 13/46 (28.2%), although not lost to
follow-up and included in ITT analysis
Selective reporting (reporting bias) High risk Comment: data on histological outcomes
not reported
Other bias Low risk Comment: no other sources of bias identi-
fied
Papadimitrakopoulou 2008
Methods Study design: RCT, parallel-group, 3 arms
Conducted in USA
Number of centres: 8
Recruitment period: November 2000 to January 2004
Funding source: Pfizer (grant support)
Study duration: 6 months
Participants Inclusion criteria
Histologically confirmed early or advanced oral pre-malignant lesion; age ≥ 18 years;
Zubrod performance status 0 to 1; haemoglobin level above lower limit of normal,
WBC count > 3000/mm3 , platelet count > 125,000/mm3 , total bilirubin, aspartate
aminotransferase and alanine aminotransferase levels V1.5 upper limit of normal, serum
creatinine V1.5 upper limit of normal; no anticipated need for treatment with oral or i.v.
corticosteroids for more than 2 consecutive weeks over any 6-month period during the
study; willingness to limit aspirin use to V100 mg/d and to abstain from chronic use of
all other non-steroidal anti-inflammatory drugs and COX-2 inhibitors for the duration
of the study
Exclusion criteria
Diagnosis of or treatment for oesophageal, gastric, pyloric channel or duodenal ulceration
within 30 days before randomisation; history of head and neck cancer in the past 18
months or of another cancer in the past 3 years (patients with a history of non-melanoma
skin cancer, cervical carcinoma in situ or chronic lymphocytic leukaemia stage 0 were
not excluded); chronic or acute renal or hepatic disorder or significant bleeding disorder;
history of or active inflammatory bowel syndrome or pancreatic disease; current use of
fluconazole or lithium
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Histological criteria for leukoplakia
Early oral pre-malignant lesion: atypical hyperplasia, atypical hyperkeratosis or mild
dysplasia. Advanced oral pre-malignant lesion: moderate to severe dysplasia
50 participants randomised: 26 females; age range 34 to 84; ethnic group: 2/50 non-
white participants, 48/50 white participants; 4/50 current smokers (8%), 27/50 current
drinkers (54%), prior oral cancer history 10/50. Early/advanced oral pre-malignant
lesion: Group A 15/2, Group B 14/1, Group C 16/2. Ten out of 32 (31%) participants
in combined active arms vs 0 of 18 in the placebo arm had a history of squamous cell
cancer of the oropharynx (9) or larynx (1). Percentage of participants with any degree of
dysplasia not reported
Group A: randomised 17, 16 completed the study
Group B: randomised 15, 13 completed the study
Group C (placebo): randomised 18, 17 completed the study
Interventions Group A: oral celecoxib 100 mg twice for 12 weeks
Group B: oral celecoxib 200 mg twice for 12 weeks
Group C: oral placebo twice daily for 12 weeks
Groups A and B were considered together in the present review
Compliance control: Compliance was measured by telephone queries and remaining
capsule counts at weeks 8 and 12
Outcomes Cancer incidence
Cancer development at 12 weeks
Clinical response
Clinical changes at 12 weeks: complete response (disappearance of all evidence of lesions)
, partial response (50% or greater decrease in the sum of products of diameters of all
measured lesions); stable disease (any response that did not meet the criteria for the other
categories), progressive disease (increase ≥ 25% in size of lesions or appearance of new
lesions or progression to invasive cancer)
Histological response
Histological changes at 12 weeks: (1) reversal of dysplasia, (2) improvement in degree of
dysplasia
Adverse events classified according to the National Cancer Institute Common Toxicity
Criteria version 2.0
Notes Follow-up from the end of treatment: 14 weeks
Quote: “After a protocol amendment in March 2003, only patients with early OPLs
continued to be randomised as just described, whereas all patients with advanced OPLs
received open-label oral celecoxib at 400mg twice daily, based again ondata of the familial
adenomatous polyposis study showing significant efficacy of celecoxib only at 400 mg
twice daily. Because this decision was made while the study was already accruing, the
400 mg twice daily open-label arm was included in an exploratory intent as an attempt
to preserve the feasibility of the study while offering a possibly superior intervention for
patients at higher cancer risk (i.e., advanced OPL). [….] Shortly after opening the 400
mg twice daily arm for patients with developedOPLs, the first reports potentially linking
use of selective COX-2 inhibitors with serious adverse cardiovascular events emerged,
leading to early closure of this arm”
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups and not likely
to have a clinically relevant impact on the
intervention effect estimate 4/50 (8%)
Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias identi-
fied
Piattelli 1999
Methods Study design: RCT, parallel-group, 2 arms
Conducted in Italy
Number of centres: 1
Recruitment period: unspecified
Funding source: partially supported by the National Research Council (CNR) and by
the Ministry of University, Research, Science and Technology (MURST), Rome, Italy
Study duration: 4 months
Participants Inclusion criteria
Histologically confirmed oral leukoplakia
Exclusion criteria
Women of childbearing age
Histological criteria for leukoplakia
Not reported
10 participants randomised: 4 females, mean age 61 (range 40 to 71), ethnic group:
Caucasian, 4 (40%) tobacco users. Mean duration of lesions: 5.8 years (range 0.5 to 20
years). Percentage of dysplastic lesions not reported
Group A: 5 randomised, 5 completed the study
Group B: 5 randomised, 4 completed the study
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Interventions Group A: 3 times daily topical application of 0.1% isotretinoin (13-cis-retinoic acid -
Roaccutane Roche) for 4 months
Group B: 3 times daily topical application of placebo (gel only), for 4 months
Compliance control: not reported
Outcomes Clinical response
Measurement of the lesion: Photography was performed before the start of treatment
and every month during treatment: Complete response was defined as complete disap-
pearance of the lesion as assessed by visual inspection; partial response was defined as a
50% or greater reduction in the size of lesions
Histological response
Evaluation of bcl-2 immunostaining.
Laboratory studies (including serum cholesterol, triglycerides, aspartate aminotrans-
ferase, alanine aminotransferase and alkaline phosphatase) were performed before the
start of treatment and every month during treatment
Notes At the end of the study period (4 months), participants who received placebo started 4-
month treatment with active medication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups and not likey to
have a clinically relevant impact on the in-
tervention effect estimate 1/10 (10%)
Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias iden-
tified
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Sankaranarayan 1997
Methods Study design: RCT, parallel-group, 3 arms
Conducted in India
Number of centres: 1
Recruitment period: unspecified
Funding source: unspecified
Study duration: 2 years (1 year of treatment + 1 year of follow-up)
Participants Inclusion criteria
Not reported
Exclusion criteria
Not reported
Histological criteria for leukoplakia
Not reported
Participant details were available only for those who completed the trial (131 participants:
47 female; mean age 50.7; 127 (97%) chewers, 41 (31%) smokers, 72 (55%) drinkers.
Percentage of dysplastic lesions not reported
Group A : randomised 50, 42 completed the study
Group B : randomised 55, 46 completed the study
Group C: randomised 55, 43 completed the study
Interventions Group A: capsules of vitamin A (300,000 IU/wk) for 1 year
Group B: capsules of beta carotene (360 mg/wk) for 1 year
Group C: capsules of placebo for 1 year
Compliance control: yes
Outcomes Cancer incidence
Malignant transformation: Biopsies were taken at baseline and during the study, when-
ever a malignant transformation was suspected. Malignant transformation was scored if
malignancy was histologically established in the lesions during follow-up
Clinical response
Number, type and dimension of lesion(s) were recorded at baseline and at each review.
(1) Complete response was defined as no clinical evidence of leukoplakia. (2) Partial
response was defined as a greater than 50% reduction in the size of the single lesion or
in the sum of sizes of multiple lesions. (3) Stable and progressive lesions were scored as
no response
Notes 160 participants randomised, all with tobacco chewing habits and leukoplakia, belonging
to the fisherman community of Trivandrum City, Kerala, India - a population with high
incidence of leukoplakia and oral cancer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind” and “subjects were
examined every 2 months during visits by
dentists and physician, both of whom were
blinded to the treatment group”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind” and “subjects were
examined every 2 months during visits by
dentists and physician, both of whom were
blinded to the treatment group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups and not likely to
have a clinically relevant impact on the in-
tervention effect estimate 29/160 (16.9%)
Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias iden-
tified
Singh 2004
Methods Study design: RCT, parallel-group, 3 arms
Conducted in India
Number of centres: unspecified
Recruitment period: unspecified
Funding source: supported by Jagsonpal Pharmaceuticals Ltd., New Delhi, India
Study duration: 3 months plus 2 months of follow-up
Participants Inclusion criteria
Not reported
Exclusion criteria
Not reported
Histological criteria for leukoplakia
Not reported
Characteristics of 58 participants who completed the study: 14 females; age: 12 partici-
pants were between 10 and 30 years, 42 were between 31 and 60 years, 4 were between
61 and 80 years; ethnic group: not reported; smoking status: not reported; alcohol status:
not reported. Percentage of dysplastic lesions: 59%
Group A: randomised 20, 20 completed the study
Group B: randomised 20, 20 completed the study
Group C: randomised 18, 18 completed the study
Interventions Group A: capsules of lycopene at high dose (8 mg/d) divided into 2 daily doses for 3
months
Group B: capsules of lycopene at low dose (4 mg/d) divided into 2 daily doses for 3
months
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Group C: capsules of placebo in 2 daily doses for 3 months
Groups A and B were considered together in the present review
Compliance control: not reported
Outcomes Clinical response
Clinical assessment was made at the third month of the study. (1) Complete response
was defined as no clinical evidence of leukoplakia for at least 4 weeks. (2) Partial response
was defined as a greater than 50% reduction in the product of the longest diameters of
the lesion. (3) Stable response was defined to occur when the decrease in lesion size was
< 50%. (4) Disease progression was defined as an unequivocal increase in the size of any
lesion during treatment, or as the appearance of a new lesion
Histological response
Histological grading was done before the start of treatment and upon its completion.
For histological evaluation, 5 stages were taken as normal, atypical hyperplasia, mild
dysplasia, moderate dysplasia and severe dysplasia. They were ranked as 0, 1, 2, 3 and
4, respectively, so that change could be quantified in terms of these ranks. For example,
a case from stage moderate dysplasia comes to stage mild dysplasia post treatment;
improvement was considered as 32¼ for 1 unit
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data. All randomised partici-
pants included in analysis of results
Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias identi-
fied
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Stich 1988
Methods Study design: RCT, parallel-group, 2 arms
Conducted in India
Number of centres: unspecified
Recruitment period: unspecified
Funding source: supported by a grant from National Cancer Institute of Canada
Study duration: 6 months
Participants Inclusion criteria
Betel quid chewers
Exclusion criteria
Not reported
Histological criteria for leukoplakia
WHO 1978
The 65 participants had tobacco chewing habits and leukoplakia, belonging to the fish-
erman community of Trivandrum City, Kerala, India - a population with high incidence
of leukoplakia and oral cancer. 2% tobacco users, 37% alcohol users, 28% tobacco +
alcohol users. Percentage of dysplastic lesions not reported
Group A: randomised 30, 21 completed the study
Group B: randomised 35, 33 completed the study
Interventions Group A: systemic capsules of vitamin A (200,000 IU/wk) for 6 months
Group B: systemic capsules of placebo for 6 months
Compliance control: yes, capsules were administered twice weekly under strict super-
vision of a local nurse
Outcomes Clinical response
Leukoplakias were evaluated before the start of treatment and at the end of the study (6
months): (1) remissionof leukoplakia, (2) no change, (3) development of new leukoplakia
Histological response
Biopsies were taken before the start of treatment and at the end of the study (6 months)
. Histological markers evaluated were (1) loss of polarity of basal cells, (2) lymphocytic
infiltration, (3) nuclei with condensed chromatin
Notes Questionnaires completed during the trial demonstrated that habits such as chewing,
smoking and drinking did not change during the course of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: insufficient information to per-
mit judgement
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
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Stich 1988 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk Proportion of lost participants (11/65)
with imbalance across intervention groups
(30% vs 5.7%)
Selective reporting (reporting bias) High risk Histological data available for only 18 par-
ticipants in the study group and for none
in the control group
Other bias Low risk Comment: no other sources of bias identi-
fied
Sun 2009
Methods Study design: RCT, parallel-group, 2 arms
Conducted in China
Number of centres: 1
Recruitment period: 1998 to 2001
Funding source: Beijing Natural Science Foundation, National Natural Science Foun-
dation of China, Tenth 5-Year Plan of National Key Technologies R&D Program in
China (No. 2004BA720A28), NIH grants
Study duration: 8 to 12 months plus 3 months of follow-up
Participants Inclusion criteria
Oral leukoplakia was defined as a white patch or plaque that cannot be characterised
clinically or pathologically as any other disease. All participating patients had general good
health without other uncontrolled medical conditions. Patients underwent a baseline
biopsy to confirm the absence of invasive cancer
Exclusion criteria
Thosewith a previous diagnosis of head andneck or oral cancer; those currently treated by
other drugs or having drug hypersensitivity; those requiring extensive dental procedures;
those with a history of social or psychiatric situations interfering with study compliance
Histological criteria for leukoplakia
Not reported
Characteristics of the 112 participants who completed the study: 43 females; age: Group
A 52.9 ± 10.4, Group B 44.4 ±11.8; ethnic group: not reported; smokers: 53/112 (47%)
; alcohol drinkers: 10/112 (9%). Percentage of participants with any dysplasia: 18.75%
(11.61% mild dysplasia, 3.57% moderate dysplasia, 3.57% severe dysplasia)
Group A: randomised 60, 59 completed the study
Group B: randomised 60, 53 completed the study
Interventions Group A: ZengShengPing - a mixture of 6 medical herbs (0.3 g per tablet) - 4 tablets
each time, 3 times a day, for 8 to 12 months (not better specified: length of the study)
Group B: placebo 4 tablets each time, 3 times a day, for 8 to 12 months (not better
specified: length of the study)
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Sun 2009 (Continued)
Compliance control: self report during monthly visit
Outcomes Clinical response
Measurement of the lesion: (1) positive response defined as disappearance or reduction
in size by more than 50% at final checkup (3 months after cessation of treatment), (2)
stable disease defined as insignificant change in the size of the lesion, (3) progressive
disease defined as increase in size of the lesion by > 50%, or development of new lesions
Histological evaluation
AgNOR and PCNA labelling index in tissues were evaluated in tissue samples before and
after treatment. Histological assessment was available for pre-treatment samples only
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned to two groups”
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups and not likely
to have a clinically relevant impact on the
intervention effect estimate 8/120 (6.6%)
Selective reporting (reporting bias) High risk Comment: information about histological
features of lesions not available
Other bias Low risk Comment: no other sources of bias identi-
fied
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Tsao 2009
Methods Study design: RCT, parallel-group, 4 arms
Conducted in Texas (USA)
Number of centres: 1
Recruitment period: August 2002 to March 2008
Funding source: supported by Ito En Ltd.
Study duration: 12 weeks and open follow-up (median 27.5 months)
Participants Inclusion criteria
Presence of 1 or more histologically confirmed, bi-dimensionally measurable OPLs that
could be sampled by biopsy and had at least 1 of the following high-risk features of
malignant transformation: harbouring at least mild dysplasia, located in a high-risk area
(i.e. floor ofmouth, ventrolateral tongue, and soft palate), significant extent ofOPL tissue
involvement, and presence of symptoms (pain or substantial discomfort). Additional
inclusion criteria included age between≥ 18 and≤ 75 years; Zubrod performance status
<2; adequate haematological, liver and renal function; adequate cardiac function (defined
as no clinically significant electrocardiogram abnormality, unstable atrial or ventricular
arrhythmias requiring medical control or ischaemic event experienced within the prior
6 months); negative pregnancy test in females of childbearing potential within 7 days
before first dose of study medication; use of effective contraceptive method while in the
trial; written informed consent for participation
Exclusion criteria
Known hypersensitivity to oral green tea extract (GTE) or its analogous, use of prior in-
vestigational agents within 30 days, any serious intercurrent illness, history of prior ma-
lignancy with less than a 1-year disease-free interval before study entry, lactating females,
patients who were not able to abstain from consumption of methylxanthine-containing
products (including coffee, tea, chocolate, caffeinated soft drinks and theophylline) and
decaffeinated tea
Histological criteria for leukoplakia
Not reported
41 participants randomised: 22 females; mean age 57 (range 33 to 76); ethnic group:
Caucasian 37/41, Hispanic 2/41, Asian 2/41; smoking status: never smoked 15/41, for-
mer smoker 22/41, current smoker 4/41; alcohol status: never 8/41, former 9/41, current
24/41. Mean duration of lesions: 5.8 years (range 0.5 to 20 years). Percentage of par-
ticipants with any dysplasia: 73.2% (56.1% mild dysplasia, 17.1% moderate/carcinoma
in situ). 34.1 % of participants had prior HNSCC, 12.2 % had prior radiotherapy (not
specified whether head and neck radiotherapy), 90.2% had prior surgery (not specified
which type of surgical therapy)
Group A: randomised 11, 11 completed the study
Group B: randomised 9, 8 completed the study
Group C: randomised 10, 9 completed the study
Group D: randomised 11, 11 completed the study
Groups A, B and C were considered together in the present review
Interventions Group A: GTE capsules (500 mg/m2 daily), given orally thrice a day after meals for 12
weeks
Group B: GTE capsules (750 mg/m2 daily) given orally thrice a day after meals for 12
weeks
Group C:GTE capsules (1000 mg/m2 daily) given orally thrice a day after meals for 12
weeks
Group D: placebo capsules given orally thrice a day after meals for 12 weeks
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Tsao 2009 (Continued)
Each capsule contained 350 mg of GTE. GTE dosage calculations were based on par-
ticipant’s body surface area according to the following formula: body surface area (m
2) = weight (kg) 0.425 × height (cm) 0.725 × 0.007184. Calculated dose was adjusted
downward to the closest dose that could be administered by using 1 or more 350-mg
capsules
Groups A, B and C were considered together in the present review
Compliance control: yes
Outcomes Cancer incidence
Cancer incidence was recorded during an open follow-up period
Clinical response
Bi-dimensional measurement of the lesion: (1) Disappearance of all lesions was consid-
ered a complete response. (2) 50% or greater decrease in the sum of products of diam-
eters of all measured lesions was considered a partial response. (3) Increase of 25% or
greater in size of lesions or appearance of new lesions or progression to invasive cancer
was considered progressive disease. (4) Any response that did not meet criteria for CR,
PR or PD was considered stable disease
Histological response
(1) Complete response was defined as a complete reversal of pre-malignancy to normal
epithelium with no new lesions. (2) Partial response was defined as improvement in
degree of maturation of epitheliumwith no new lesions and no progression of any lesion.
(3) Stable disease was defined as no change in histology and no appearance of new lesions
or progression of any lesion. (4) Progression of disease was defined as progression from
hyperplasia and/or hyperkeratosis to dysplasia, or from a lower to a higher degree of
dysplasia or invasive carcinoma, or appearance of any new lesions
Notes Quote: “With a median follow-up time of 27.5 months, 15 patients subsequently de-
veloped oral cancer with a median time to oral cancer development of 46.4 months.”
It is not specified how they were distributed in the 3 arms, but (quote): “There was no
difference in oral cancer-free survival between the GTE and placebo arms”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation was done
with the Pocock-Simon dynamic alloca-
tion scheme to balance three prognostic
factors in each of the four arms. The
prognostic factors were tobacco use (cur-
rent, stopped, never), alcohol use (current,
stopped, never), and tea use (zero to four
8-oz cups daily or five or more 8-oz cups
daily)
Allocation concealment (selection bias) Unclear risk Comment: insufficient information to per-
mit judgement
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Tsao 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient information to per-
mit judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomedata balanced innumbers
across intervention groups and not likely
to have a clinically relevant impact on the
intervention effect estimate 2/41 (5%)
Selective reporting (reporting bias) Low risk Comment: important outcomes and ad-
verse effects reported
Other bias Low risk Comment: no other sources of bias identi-
fied
AgNOR = silver-stained nucleolar organizer region
CNR = National Research Council
COX = cyclo-oxygenase
CR = complete response
EGFR = epidermal growth factor receptor
FU = follow-up
HNSCC = head and neck squamous cell carcinoma
ITT = intention-to-treat
MURST = Ministry of University, Research, Science and Technology
NIH = National Institutes of Health
OIN = oral intraepithelial neoplasia
OPL = oral pre-malignant lesion
OSCC = oral squamous cell carcinoma
PCNA = proliferation cell nuclear antigen
PD = progressive disease
PR = partial response
RCT = randomised controlled trial
SCC = squamous cell carcinoma
WHO = World Health Organization
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bocharova 2004 The study was not randomised, and both arms of the study employed active treatments, i.e. no placebo (or
no treatment) group was included in the study
Boisnic 1994 The study included participants with traumatic lesions
Chee 2013 Both arms of the study employed active treatments, i.e. no placebo (or no treatment) group was included in
the study
Chiesa 2005 All participants underwent active treatment. The aim of the treatment tested was to prevent recurrence of
leukoplakia; all participants were randomised after surgical removal (active treatment) of the oral lesion
Femiano 2001 The study was not randomised, and participants were allocated to study arms by researchers
Gaeta 2000 Quasi-randomised trial
Garewal 1999 Participants randomised were a selected group who responded to the drug tested in the randomised phase
(beta carotene)
Krishnaswamy 1995 The study used an inadequate method of allocation, and only 66% of participants had lesions, none with a
histological diagnosis
Lippman 1993 Participants randomised were a selected group who responded to 1 of the 2 drugs tested during the randomised
phase (isotretinoin)
López-Jornet 2013 Both arms of the study employed active treatments, i.e. no placebo (or no treatment) group was included in
the study
Mathew 1995 The study was not randomised, as controls were taken from another study control group
Schwarz 2005 Both arms of the study employed active treatments, i.e. no placebo (or no treatment) group was included in
the study
Zaridze 1993 The oral lesions diagnosed as leukoplakia were not biopsied for histological examination. Data, as presented
in the paper, do not allow analysis
Characteristics of studies awaiting assessment [ordered by study ID]
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Califano 2012
Methods
Participants Inclusion criteria
(1) Presence of 3p, 9p21 or 17p LOH, and/or (2) surgically unresectable high-grade pre-malignant lesions and/or
(3) high-grade pre-malignancy after curative therapy for HNSCC
Interventions Participants received cetuximab 400 mg/m2 week 1 followed by 250 mg/m2 weeks 2 to 8 or observation, with the
option for cross-over to cetuximab for participants originally randomised to the observation arm
Outcomes Histological grade (1 = benign, 2 = mild dysplasia, 3 = moderate dysplasia, 4 = severe dysplasia/carcinoma in situ, 5
= invasive cancer) and change in grade of dysplasia were evaluated. Malignant transformation was evaluated
Notes
Chiba 2012
Methods Study design: RCT, parallel-group, 2 arms
Conducted in Sri Lanka
Number of centres: 15
Recruitment period: unspecified
Funding source: unspecified
Study duration: unspecified
Participants Inclusion criteria
Betel quid chewers with pathological diagnosis of oral pre-cancer
Exclusion criteria
Lesion not measurable
Histological criteria for leukoplakia
Not reported
72 participants randomised: mean age 53.9, 90.2% male, ethnic 98.6% Sinhala. Percentage of dysplastic lesions not
reported
Group A: unspecified
Group B: unspecified
Interventions Group A: curcumin-coated chewing gum
Group B: placebo chewing gum
Compliance control: not reported
Outcomes Clinical response
Lesions were measured every 6 months. Participants were followed up every month by oral and maxillofacial surgeons
at each hospital
Histological response
Not reported
Notes The only available report of this study is an abstract
HNSCC = head and neck squamous cell carcinoma
59Interventions for treating oral leukoplakia to prevent oral cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
LOH = loss of heterozygosity
RCT = randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT00004161
Trial name or title Fenretinide in treating patients with leukoplakia of the mouth
Methods Study design: RCT, parallel-group
Participants Inclusion criteria: histologically proven dysplastic leukoplakia > 1 cm in diameter, age 18 and older
Interventions Group A: oral fenretinide daily (except days 1 to 3 each month) for 6 months
Group B: oral placebo daily (except days 1 to 3 each month) for 6 months, then oral fenretinide daily (except
days 1 to 3 each month) for 6 months. Participants are followed up every 3 months
Outcomes Regression of oral dysplastic leukoplakia
Intermediate endpoint markers
Surrogate endpoint biomarkers
Recurrence rate of oral dysplastic leukoplakia after administration of fenretinide, both at the same site and at
new sites
Starting date February 2000
Contact information Samuel W. Beenken; University of Alabama at Birmingham
Notes Status: completed (the study has ended normally, and participants are no longer being examined or treated)
NCT00014404
Trial name or title Celecoxib in treating patients with precancerous lesions of the mouth
Methods Study design: RCT, parallel-group
Participants Inclusion criteria: histologically confirmed index oral pre-malignant lesion
Interventions Group A: lower-dose oral celecoxib twice daily
Group B: higher-dose oral celecoxib twice daily
Group C: oral placebo twice daily
Treatment continues in all 3 arms for 12 weeks in the absence of disease progression or unacceptable toxicity.
Participants are followed at 18, 24 and 26 weeks
Outcomes
Starting date October 2000
Contact information Jay O Boyle, Study Chair; Memorial Sloan-Kettering Cancer Center
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NCT00014404 (Continued)
Notes This study is no longer recruiting participants
NCT00101335
Trial name or title Celecoxib in preventing head and neck cancer in patients with oral leukoplakia
Methods Study design: cross-over RCT
Participants Inclusion criteria: diagnosis of oral leukoplakia with hyperplasia or dysplasia
Interventions Group A: oral celecoxib twice daily for 3 months
Group B: oral placebo twice daily for 3 months
All participants undergo biopsy. Participants then cross over to the opposite treatment arm for 3 months
Outcomes Primary: regression of oral leukoplakia lesions in participants with hyperplastic or dysplastic oral leukoplakia
Secondary: multiple intermediate biomarkers (e.g. COX-2, PPARγ , PPARδ) in normal and hyperplastic or
dysplastic oral epithelia of participants; safety; cost-effectiveness
Starting date 2005
Contact information Paul F. Engstrom; Fox Chase Cancer Center
Notes Status: completed (the study has ended normally, and participants are no longer being examined or treated)
NCT00155337
Trial name or title Photodynamic therapy for oral leukoplakia and erythroleukoplakia
Methods Study design: RCT, parallel-group
Participants Inclusion criteria: patients with leukoplakia or erythroleukoplakia, age 20 to 80 years
Exclusion criteria: oral cancers
Interventions Group A: photodynamic therapy
Group B: unclear
Outcomes Regression of lesions
Starting date 2005
Contact information Chun-Pin Chiang; National Taiwan University Hospital
Notes Status: completed (the study has ended normally, and participants are no longer being examined or treated)
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NCT00176566
Trial name or title A phase II trial to assess the effects of green tea in oral leukoplakia
Methods Study design: RCT, parallel-group
Participants Inclusion criteria: patients with oral leukoplakia without evidence of active infection
Exclusion criteria: allergy to caffeine, GI ulcers, pregnancy, previous invasive mouth cancer
Interventions Group A: green tea lozenge
Group B: placebo
Outcomes Primary outcomes: prevalence, size, histological severity of oral leukoplakia
Starting date 2005
Contact information Susan Goodin, PharmD; University of Medicine and Dentistry New Jersey
Notes Status: terminated (the study has stopped recruiting or enrolling participants early and will not start again;
participants are no longer being examined or treated)
NCT00299195
Trial name or title A randomized study of sulindac in oral premalignant lesions
Methods Study design: RCT, parallel-group
Participants Inclusion criteria: oral pre-malignant lesion (OPL) defined as a lesion that can include atypical hyperplasia,
atypical hyperkeratosis, leukoplakia and erythroplakia/erythro-leukoplakia
Interventions Drug: sulindac 150 mg p.o. b.i.d. × 24 weeks
Drug: placebo b.i.d. × 24 weeks
Outcomes To evaluate the efficacy of sulindac in participants with early or advanced oral pre-malignant lesion (OPL) by
both clinical response (reduction in size of all lesions) and histological response (change in histological grade)
Starting date 2006
Contact information Jay O. Boyle; Memorial Sloan-Kettering Cancer Center
Notes Status: This study is ongoing but is not recruiting participants
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NCT00402779
Trial name or title Erlotinib prevention of oral cancer (EPOC)
Methods Study design: RCT, parallel-group
Participants Inclusion criteria
Male or female patients with 1 of the following: (1) loss of heterozygosity (LOH) at 3p14 and/or 9p21 in the
oral Intraepithelial neoplasia (IEN) of patients with a history of curatively treated oral cancer, or (2) LOH at
3p14 and/or 9p21 plus at 1 other chromosomal region in the IEN of participants with no oral cancer history;
participants must have confirmed diagnosis of oral IEN lesion with LOH; age ≥ 18 years
Interventions Group A: erlotinib 150 mg for 1 year
Group B: placebo for 1 year
Outcomes Primary outcome: oral cancer-free survival
Secondary outcomes: Size, number and appearance of oral IEN will be assessed and correlated with cancer
risk; a panel of molecular markers will be used for correlation with oral cancer development in our participants
with oral IEN
Starting date 2006
Contact information Vassiliki Papadimitrakopoulou; M.D. Anderson Cancer Center
Notes Status: This study is ongoing but is not recruiting participants
NCT00951379
Trial name or title Pioglitazone for oral premalignant lesions
Methods
Participants Inclusion criteria
STAGE I: males or females with suspected or histologically confirmed oral premalignant lesion(s)
Interventions Group A: pioglitazone hydrochloride p.o. q.d. for 24 weeks
Group B: placebo p.o. q.d. for 24 weeks
Outcomes Primary outcome measures
Clinical and histological response defined as 50% or greater reduction in the sum of measured products of
perpendicular dimensions of target lesion(s), or improvement in the degree of dysplasia or hyperplasia
Secondary outcome measures
Tissue levels of PPAR gamma, cyclin D1 and p21 as indirect measures of pharmacological effect, TUNEL for
apoptosis andKi-67 for proliferation, transglutaminase and involucrin asmarkers of squamous differentiation,
15-PGDH and loss of heterozygosity. Level of C-reactive protein in plasma. Tobacco and alcohol use. Adverse
events and clinical laboratory toxicity assessed by National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0
Starting date 2010
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NCT00951379 (Continued)
Contact information Jay Boyle; M.D. Anderson Cancer Center
Notes Status: This study is currently recruiting participants
NCT01497951
Trial name or title Photodynamic therapy for oral precursor lesions (PDT)
Methods Study design: RCT, parallel-group
Participants Inclusion criteria
Existing leukoplakia simplex SIN III (diagnostics by biopsy); leukoplakia verrucosa without indications of
malignant changes (diagnostics by biopsy); oral lichen planus SIN III (diagnostics by biopsy)
Interventions Group A: aminolaevulinic acid
Group B: placebo
Outcomes Primary outcome: changes in per cent (%) of initial area in mm2
Secondary outcomes: pain due to treatment, assessed by visual analogue scale (VAS)
Starting date 2011
Contact information Georg Watzek; Medical University of Vienna
Notes Status: This study is currently recruiting participants
COX = cyclo-oxygenase
CTCAE = Common Terminology Criteria for Adverse Events
EPOC = excess post-exercise oxygen consumption
IEN = intraepithelial neoplasia
Ki-67 = protein; cellular marker of neoplasia
NCI = National Cancer Institute
OPL = oral pre-malignant lesion
PDT = photodynamic therapy
PGDH = 15-hydroxyprostaglandin dehydrogenase
PPAR = peroxisome proliferator-activated receptor
RCT = randomised controlled trial
SIN = squamous intraepithelial neoplasia
TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labeling
VAS = visual analogue scale
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin A or retinoids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral cancer development 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Systemic treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Clinical resolution 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Systemic treatment 3 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Topical treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Improvement of histological
features
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Systemic treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Beta carotene or carotenoids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral cancer development 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Systemic treatment 2 132 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.24, 2.09]
2 Clinical resolution 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Systemic treatment 3 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Improvement of histological
features
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Systemic treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. NSAIDs versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical resolution 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Systemic treatment 1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.83, 1.08]
1.2 Topical treatment 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.81, 1.10]
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Comparison 4. Herbal extracts versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical resolution 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Systemic treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Topical treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Systemic plus topical
treatment
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Improvement of histological
features
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Systemic treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Topical treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Topical bleomycin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Oral cancer development 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Clinical resolution 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Improvement of histological
features
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 6. Bowman-Birk inhibitor versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical resolution 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Analysis 1.1. Comparison 1 Vitamin A or retinoids versus placebo, Outcome 1 Oral cancer development.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 1 Vitamin A or retinoids versus placebo
Outcome: 1 Oral cancer development
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Sankaranarayan 1997 0/42 4/43 0.11 [ 0.01, 2.05 ]
0.005 0.1 1 10 200
Favours treatment Favours placebo
Analysis 1.2. Comparison 1 Vitamin A or retinoids versus placebo, Outcome 2 Clinical resolution.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 1 Vitamin A or retinoids versus placebo
Outcome: 2 Clinical resolution
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Stich 1988 9/21 32/33 0.44 [ 0.27, 0.73 ]
Sankaranarayan 1997 20/42 40/43 0.51 [ 0.37, 0.71 ]
Hong 1986 20/22 18/18 0.92 [ 0.78, 1.08 ]
2 Topical treatment
Piattelli 1999 4/5 4/4 0.83 [ 0.48, 1.44 ]
0.5 0.7 1 1.5 2
Favours treatment Favours placebo
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Analysis 1.3. Comparison 1 Vitamin A or retinoids versus placebo, Outcome 3 Improvement of histological
features.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 1 Vitamin A or retinoids versus placebo
Outcome: 3 Improvement of histological features
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Hong 1986 8/21 16/18 0.43 [ 0.24, 0.76 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
Analysis 2.1. Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 1 Oral cancer
development.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 2 Beta carotene or carotenoids versus placebo
Outcome: 1 Oral cancer development
Study or subgroup Treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Sankaranarayan 1997 2/46 4/43 58.5 % 0.47 [ 0.09, 2.42 ]
Nagao 2015 3/21 3/22 41.5 % 1.05 [ 0.24, 4.62 ]
Subtotal (95% CI) 67 65 100.0 % 0.71 [ 0.24, 2.09 ]
Total events: 5 (Treatment), 7 (Placebo)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
0.002 0.1 1 10 500
Favours treatment Favours placebo
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Analysis 2.2. Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 2 Clinical resolution.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 2 Beta carotene or carotenoids versus placebo
Outcome: 2 Clinical resolution
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Nagao 2015 20/21 22/22 0.95 [ 0.84, 1.08 ]
Sankaranarayan 1997 31/46 40/43 0.72 [ 0.58, 0.90 ]
Singh 2004 24/40 18/18 0.61 [ 0.47, 0.80 ]
0.5 0.7 1 1.5 2
Favours treatment Favours placebo
Analysis 2.3. Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 3 Improvement of
histological features.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 2 Beta carotene or carotenoids versus placebo
Outcome: 3 Improvement of histological features
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Singh 2004 8/40 15/18 0.24 [ 0.12, 0.46 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
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Analysis 3.1. Comparison 3 NSAIDs versus placebo, Outcome 1 Clinical resolution.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 3 NSAIDs versus placebo
Outcome: 1 Clinical resolution
Study or subgroup Treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Papadimitrakopoulou 2008 27/29 17/17 100.0 % 0.94 [ 0.83, 1.08 ]
Subtotal (95% CI) 29 17 100.0 % 0.94 [ 0.83, 1.08 ]
Total events: 27 (Treatment), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
2 Topical treatment
Mulshine 2004 33/37 18/19 100.0 % 0.94 [ 0.81, 1.10 ]
Subtotal (95% CI) 37 19 100.0 % 0.94 [ 0.81, 1.10 ]
Total events: 33 (Treatment), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
0.5 0.7 1 1.5 2
Favours treatment Favours placebo
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Analysis 4.1. Comparison 4 Herbal extracts versus placebo, Outcome 1 Clinical resolution.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 4 Herbal extracts versus placebo
Outcome: 1 Clinical resolution
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Tsao 2009 27/28 11/11 0.99 [ 0.86, 1.14 ]
2 Topical treatment
Mallery 2014 2/22 0/18 4.13 [ 0.21, 80.91 ]
3 Systemic plus topical treatment
Li 1999 29/29 30/30 1.00 [ 0.94, 1.07 ]
0.005 0.1 1 10 200
Favours treatment Favours placebo
Analysis 4.2. Comparison 4 Herbal extracts versus placebo, Outcome 2 Improvement of histological
features.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 4 Herbal extracts versus placebo
Outcome: 2 Improvement of histological features
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Systemic treatment
Tsao 2009 22/28 10/11 0.86 [ 0.66, 1.13 ]
2 Topical treatment
Mallery 2014 13/22 11/18 0.97 [ 0.58, 1.60 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
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Analysis 5.1. Comparison 5 Topical bleomycin versus placebo, Outcome 1 Oral cancer development.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 5 Topical bleomycin versus placebo
Outcome: 1 Oral cancer development
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Epstein 1994 2/8 1/12 3.00 [ 0.32, 27.83 ]
0.002 0.1 1 10 500
Favours treatment Favours placebo
Analysis 5.2. Comparison 5 Topical bleomycin versus placebo, Outcome 2 Clinical resolution.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 5 Topical bleomycin versus placebo
Outcome: 2 Clinical resolution
Study or subgroup Treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Epstein 1994 5/10 11/12 0.55 [ 0.29, 1.04 ]
0.005 0.1 1 10 200
Favours treatment Favours placebo
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Analysis 5.3. Comparison 5 Topical bleomycin versus placebo, Outcome 3 Improvement of histological
features.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 5 Topical bleomycin versus placebo
Outcome: 3 Improvement of histological features
Study or subgroup Treatment Placebo Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Epstein 1994 4/10 9/11 0.49 [ 0.22, 1.10 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
Analysis 6.1. Comparison 6 Bowman-Birk inhibitor versus placebo, Outcome 1 Clinical resolution.
Review: Interventions for treating oral leukoplakia to prevent oral cancer
Comparison: 6 Bowman-Birk inhibitor versus placebo
Outcome: 1 Clinical resolution
Study or subgroup Treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Armstrong 2013 41/43 44/46 1.00 [ 0.91, 1.09 ]
0.5 0.7 1 1.5 2
Favours treatment Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Participants with dysplastic leukoplakia
Study Participants with dysplastic leukoplakia (any grade)
Armstrong 2013 Not reported
Epstein 1994 22%
Hong 1986 27%
Li 1999 20%
Mallery 2014 72.5%
Mulshine 2004 Not reported
Nagao 2015 Not reported
Papadimitrakopoulou 2008 Not reported
Piattelli 1999 Not reported
Sankaranarayan 1997 Not reported
Singh 2004 59%
Stich 1988 Not reported
Sun 2009 18.75%
Tsao 2009 73.2%
Table 2. Participants reporting adverse effects
Study Arms Active treatment Placebo Adverse effects
Armstrong 2013 Bowman Birk inhibitor
concentrate vs placebo
75 reported from 33 of
67 participants
63 reported from 25 of
65 participants
Minor adverse effects
Epstein 1994 Topical bleomycin vs
placebo
10/10 0/12 Bleomycin group - ery-
thema and ero-
sion (100%), discomfort
(60%)
Placebo group - ery-
thema only
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Table 2. Participants reporting adverse effects (Continued)
Hong 1986 Systemic 13-cis-retinoic
acid (from 1 to 2 mg/kg
per day) vs placebo
19/24 4/20 Cheilitis,
facial erythema, dryness
and peeling of skin, con-
junctivitis, hypertriglyc-
eridaemia
Li 1999 Systemic and topical tea
vs placebo
Not measured or re-
ported
Mallery 2014 Freeze-dried black rasp-
berry gel vs placebo gel
0/22 0/18 “No participant experi-
enced any treatment-as-
sociated complications”
Mulshine 2004 Ketorolac oral rinse vs
placebo
11/38 3/19 Pain, toxicity grade 1 and
2
Nagao 2015 Beta carotene and vita-
min C vs placebo
0/23 0/23 No untoward side effects
were noted
Papadimitrakopoulou
2008
Celecoxib vs placebo 56 reported from 32 par-
ticipants
20 reported from 18 par-
ticipants
4 participants presented
grade 3 adverse events:
2 in placebo arm and 2
in active treatment arm.
2 participants from in-
tervention groups dis-
continued treatment ow-
ing to adverse effects (1
grade 2 and 1 grade 3)
Piattelli 1999 Topical 13-cis-retinoic
acid vs placebo
0/5 0/5 “No side effects from the
use of the gel
were ever observed”
Sankaranarayan 1997 Vitamin A (300,000 IU
per week) vs placebo
13/50 1/55 Headache, muscular
pain, dry mouth
Sankaranarayan 1997 Beta carotene (360 mg
per week) vs placebo
5/55 1/55 Headache, muscular
pain
Singh 2004 Lycopene (8mg or 4mg)
vs placebo
0/40 0/18 “No side effects, toxicity
of any sort were encoun-
tered in the complete du-
ration of the therapy”
Stich 1988 Vitamin A (200,000 IU
per week) vs placebo
0/30 0/35 “The administered doses
of vitaminA did not pro-
duce any detectable ad-
verse
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Table 2. Participants reporting adverse effects (Continued)
effects during the trial
period”
Sun 2009 Chinese herbal mixture
vs placebo
Not measured or re-
ported
Tsao 2009 Green tea extract at dif-
ferent doses (500, 750
or 1000 mg/m2 daily) vs
placebo
28/30 8/11 Grade 1 to 2 adverse
events including insom-
nia, headache, nausea
and nervousness
vs = versus
Table 3. Participants leaving the studies
Study Arms Active treatment Placebo
Armstrong 2013 Bowman Birk inhibitor concen-
trate vs placebo
24/67 19/65
Epstein 1994 Topical bleomycin vs placebo 0/10 1/12
Hong 1986 Systemic 13-cis-retinoic acid
(from 1 to 2 mg/kg per day) vs
placebo
2/24 2/20
Li 1999 Systemic and topical tea vs
placebo
3/32 2/32
Mallery 2014 Freeze-dried black raspberry gel
vs placebo gel
0/22 0/18
Mulshine 2004 Ketorolac oral rinse vs placebo 1/38 0/19
Nagao 2015 Beta carotene and vitamin C vs
placebo
5/23 5/23
Papadimitrakopoulou 2008 Celecoxib vs placebo 3/32 1/18
Piattelli 1999 Topical 13-cis-retinoic acid vs
placebo
0/5 1/5
Sankaranarayan 1997 Vitamin A (300,000 IU per
week) vs placebo
8/50 12/55
Sankaranarayan 1997 Beta carotene (360 mg per week)
vs placebo
9/55 12/55
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Table 3. Participants leaving the studies (Continued)
Singh 2004 Lycopene (8 mg or 4 mg) vs
placebo
0/40 0/18
Stich 1988 Vitamin A (200,000 IU per
week) vs placebo
9/30 2/35
Sun 2009 Chinese herbal mixture vs
placebo
1/60 7/60
vs = versus
A P P E N D I C E S
Appendix 1. MEDLINE Ovid search strategy
1. exp Leukoplakia, Oral/
2. (erythroplak$ or erythroleukoplak$).ti,ab.
3. (leukoplak$ adj (oral or mucosa$ or mouth$)).ti,ab.
4. (keratosis adj (oral or mucosa$ or mouth$)).ti,ab.
5. (leukokeratosis adj (oral or mucosa$ or mouth$)).ti,ab.
6. ((precancer$ or pre-cancer$ or preneoplas$ or pre-neoplas$) adj6 (oral or mouth$ or mucosa$)).ti,ab.
7. ((white adj (spot$ or lesion$ or patch$)) and (mouth$ or oral or mucosa$)).ti,ab.
8. “oral dysplasia”.ti,ab.
9. or/1-8
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in
MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of The Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011] (Higgins 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
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Appendix 2. Cochrane Oral Health’s Trials Register search strategy
(leukoplak* or erthroplak* or erythroleukoplak* or keratosis or leukokeratosis or precancer or pre-cancer or preneoplas* or pre-neoplas*
or “white spot*” or “white lesion*” or “white patch*” or “oral dysplasia”)
Appendix 3. The Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1 MeSH descriptor Leukoplakia, Oral this term only
#2 (erythroplak* in All Text or erythroleukoplak* in All Text)
#3 (oral next leukoplak* in All Text or mucosa* next leukoplak* in All Text or mouth* next leukoplak* in All Text)
#4 (oral next keratosis in All Text or muscoa* next keratosis in All Text or mouth* next keratosis in All Text)
#5 (oral next leukokeratosis in All Text or muscoa* next leukokeratosis in All Text or mouth* next leukokeratosis in All Text)
#6 ( (precancer* in All Text near/6 oral in All Text) or (pre-cancer in All Text near/6 oral in All Text) or (preneoplas* in All Text near/
6 oral in All Text) or (pre-neoplas* in All Text near/6 oral in All Text) )
#7 ( (precancer* in All Text near/6 mouth* in All Text) or (pre-cancer in All Text near/6 mouth* in All Text) or (preneoplas* in All
Text near/6 mouth* in All Text) or (pre-neoplas* in All Text near/6 mouth* in All Text) )
#8 ( (precancer* in All Text near/6 mucosa* in All Text) or (pre-cancer in All Text near/6 mucosa* in All Text) or (preneoplas* in All
Text near/6 mucosa* in All Text) or (pre-neoplas* in All Text near/6 mucosa* in All Text) )
#9 ( (“white spot*” in All Text near/6 mouth* in All Text) or (“white lesion*” in All Text near/6 mouth* in All Text) or (“white patch*”
in All Text near/6 mouth* in All Text) )
#10 ( (“white spot*” in All Text near/6 oral in All Text) or (“white lesion*” in All Text near/6 oral in All Text) or (“white patch*” in All
Text near/6 oral in All Text) )
#11 ( (“white spot*” in All Text near/6 mucosa* in All Text) or (“white lesion*” in All Text near/6 mucosa* in All Text) or (“white
patch*” in All Text near/6 mucosa* in All Text) )
#12 “oral dysplasia” in All Text
#13 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12)
Appendix 4. Embase Ovid search strategy
1. Leukoplakia/
2. (erythroplak$ or erythroleukoplak$).ti,ab.
3. (leukoplak$ adj (oral or mucosa$ or mouth$)).ti,ab.
4. (keratosis adj (oral or mucosa$ or mouth$)).ti,ab.
5. (leukokeratosis adj (oral or mucosa$ or mouth$)).ti,ab.
6. ((precancer$ or pre-cancer$ or preneoplas$ or pre-neoplas$) adj6 (oral or mouth$ or mucosa$)).ti,ab.
7. ((white adj (spot$ or lesion$ or patch$)) and (mouth$ or oral or mucosa$)).ti,ab.
8. “oral dysplasia”.ti,ab.
9. or/1-8
The above subject search was linked to the Cochrane Oral Health Group filter for identifying RCTs in EMBASE via OVID:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
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14. or/1-13
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
16. 14 NOT 15
Appendix 5. CancerLit (PubMed) search strategy
#1 Oral leukoplakia [mh:exp]
#2 oral AND leukoplak*[Title/Abstract]
#3 mucosa* AND leukoplak*[Title/Abstract]
#4 mouth* AND leukoplak*[Title/Abstract]
#5 erthroplak* or erythroleukoplak*[Title/Abstract]
#6 oral AND keratosis[Title/Abstract]
#7 mouth* AND keratosis [tiab]
#8 oral AND leukokeratosis [tiab]
#9 mucosa* AND leukokeratosis [tiab]
#10 mouth* AND leukokeratosis [tiab]
#11 precancer* AND oral [tiab]
#12 pre-cancer* AND oral [tiab]
#13 preneoplas* AND oral [tiab]
#14 pre-neoplas* AND oral [tiab]
#15 precancer* AND mouth*
#16 pre-cancer* AND mouth* [tiab]
#17 preneoplas* AND mouth* [tiab]
#18 pre-neoplas* AND mouth* [tiab]
#19 precancer* AND mucosa* [tiab]
#20 pre-cancer* AND mucosa* [tiab]
#21 preneoplas* AND mucosa* [tiab]
#22 pre-neoplas* AND mucosa* [tiab]
#23 “white spot*” AND mouth* [tiab]
#24 “white spot*” AND oral [tiab]
#25 “white spot*” AND mucosa* [tiab]
#26 “white lesion*” AND mouth* [tiab]
#27 “white lesion*” AND oral [tiab]
#28 “white lesion*” AND mucosa* [tiab]
#29 “white patch*” AND mouth* [tiab]
#30 “white patch*” AND oral [tiab]
#31 “white patch*” AND mucosa* [tiab]
#32 oral AND dysplasia [tiab]
#33 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in
MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.a of The Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011] (Higgins 2011).
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
#3 randomized [tiab]
#4 placebo [tiab]
#5 drug therapy [sh]
#6 randomly [tiab]
#7 trial [tiab]
#8 groups [tiab]
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
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#10 animals [mh] not humans [mh]
#11 #9 NOT #10
[limits: Cancer]
Appendix 6. Trials registries search strategies
metaRegister of Controlled Trials search strategy
leukoplakia
ClinicalTrials.gov search strategy
“oral leukoplakia”
WHO International Clinical Trials Registry Platform search strategy
“oral leukoplakia”
WH A T ’ S N E W
Last assessed as up-to-date: 16 May 2016.
Date Event Description
30 June 2016 New citation required but conclusions have not changed 6 new studies included. 1 previously included study has
been excluded, as it was quasi-randomised (Gaeta 2000)
16 May 2016 New search has been performed Search updated
H I S T O R Y
Protocol first published: Issue 3, 1999
Review first published: Issue 4, 2001
Date Event Description
5 August 2008 Amended Converted to new review format
4 July 2006 New citation required but conclusions have not changed Reviewupdated. 2new included studies (Mulshine 2004;
Singh 2004), 3 new ongoing studies, 3 newly excluded
studies. Conclusions remained essentially the same
80Interventions for treating oral leukoplakia to prevent oral cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
25 May 2004 New citation required but conclusions have not changed Review updated. 1 new study (Gaeta 2000) has been in-
cluded, but summary estimates did not change signifi-
cantly, and conclusions remained essentially the same
C O N T R I B U T I O N S O F A U T H O R S
Giovanni Lodi: main review author, participation in all phases of review preparation
Roberto Franchini: selection of articles, data extraction, text preparation
Elena Varoni: data extraction, interpretation of studies
Saman Warnakulasuriya: interpretation of results, text preparation
Andrea Sardella: selection of articles, interpretation of results
Alexander R Kerr: interpretation of results, text preparation
Antonio Carrassi: group co-ordinator, interpretation of results
LCI MacDonald: updated text, data extraction and analysis, quality assessment
Helen V Worthington: data extraction and analysis, quality assessment
D E C L A R A T I O N S O F I N T E R E S T
Giovanni Lodi: none known
Roberto Franchini: none known
Saman Warnakulasuriya: none known
Elena Maria Varoni: none known
Andrea Sardella: none known
Alexander R Kerr: none known
Antonio Carrassi: none known
LCI MacDonald: none known. LM is a salaried member of staff with Cochrane Oral Health
Helen V Worthington: none known. HW is a Co-ordinating Editor with Cochrane Oral Health
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S O U R C E S O F S U P P O R T
Internal sources
• Università degli Studi di Milano, Italy.
External sources
• School of Dentistry, The University of Manchester, UK.
• Cochrane Oral Health Group Global Alliance, Other.
Through our Global Alliance (http://ohg.cochrane.org/partnerships-alliances), the Cochrane Oral Health Group has received
support from British Association for the Study of Community Dentistry, UK; British Association of Oral Surgeons, UK; British
Orthodontic Society, UK; British Society of Paediatric Dentistry, UK; British Society of Periodontology, UK; Canadian Dental
Hygienists Association, Canada; Mayo Clinic, USA; National Center for Dental Hygiene Research & Practice, USA; New York
University College of Dentistry, USA; NHS Education for Scotland (NES); and Royal College of Surgeons of Edinburgh, UK
• National Institute for Health Research (NIHR), UK.
This project was supported by the NIHR, via Cochrane Infrastructure funding to the Cochrane Oral Health Group. The views and
opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme,
NIHR, National Health Service (NHS) or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the title to specify that oral leukoplakia is treated to prevent oral cancer.
When it was not possible to obtain missing data from trial authors, and we found no evidence that data were missing because of a
specific bias, we analysed only available data (Higgins 2011). This represents a change from the previous version of the review, wherein
missing data were imputed with the assumption that all were poor outcomes.
We used fixed-effect rather than random-effects meta-analysis because of the small number of included studies.
In accordance with the methodological recommendations of Cochrane Oral Health, we now include only randomised controlled trials
to reduce risk of bias from quasi-randomised studies. Therefore, we have excluded the small, quasi-randomised study (Gaeta 2000)
from this version of the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Leukoplakia, Oral [∗therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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